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Introduction: Previous studies have linked an insertion/deletion polymorphism in the
angiotensin-converting enzyme (ACE) gene with variability in the response of muscle
strength and mass to strength training, though conclusions have been inconsistent across
investigations. The purpose of this study was to investigate the possible association
between ACE genotype and skeletal muscle strength and volume, and their adaptation to
strength training. Methods: A group of older, sedentary adults completed 10-weeks of
strength training. Quadriceps muscle strength and volume were measured using one
repetition maximum and computed tomography, respectively. Differences were
compared among ACE genotype groups (II vs. ID+DD) by sex and race. Results:
Baseline and post-training, skeletal muscle strength and volume were not significantly
correlated with ACE genotype. ACE genotype was significantly associated with muscle
hypertrophy in Caucasian males only (p=0.02). Conclusions: The ACE genotype was
not associated with skeletal muscle strength, but was associated with muscle hypertrophy
in Caucasian males.
ASSOCIATION BETWEEN ACE GENOTYPE AND SKELETAL MUSCLE




Thesis submitted to the Faculty of the Graduate School of the
University of Maryland, College Park in partial fulfillment




Assistant Professor Stephen Roth, Chair
Professor Ben Hurley















Appendix A – Limitations 30-31
Appendix B – Abbreviations 32
Appendix C – Statistical Power 33-35
Appendix D – Review of Literature 36-68




I would like to thank my friends and family for all of their love and support
throughout my pursuit of my graduate education. The help that they gave me in working
through the difficult and frustrating times will not be forgotten. In particular I would like
to thank my brother, Andrew, and my parents for their unconditional support.
I would also like to acknowledge my advisor, Dr. Stephen Roth. The guidance
and support that he provided were pivotal in the completion of not only this thesis project
but also my graduate degree. His communication, advice, knowledge, and availability
made him an effective mentor as well as a valuable source of support and stability.
Finally, I would like to thank my committee members, Dr. Espen Spangenburg
and Dr. Ben Hurley for their willingness to serve on my thesis committee. I appreciate
the time and effort that they committed toward the completion of this project. I would
also like to thank Dr. Ben Hurley for allowing me to be a part of the GUSTO training
study from which this thesis project was formed.
iv
List of Tables
Table 1: Subject characteristics by sex & ACE genotype 13
Table 2: Subject characteristics by sex and ACE genotype group 14
Table 3: Subject characteristics by sex and race 14
Table 4: ACE genotype & allele frequencies by race 15
Table 5: Muscle strength in males and females grouped by ACE genotype 16
Table 6: Muscle volume in males and females grouped by ACE genotype 17
Table 7: Muscle strength in Caucasian and African American males
grouped by ACE genotype 18
Table 8: Muscle strength in Caucasian and African American females
grouped by ACE genotype 19
Table 9: Muscle volume in Caucasian and African American males
grouped by ACE genotype 20
Table 10: Muscle volume in Caucasian and African American females
grouped by ACE genotype 20
1
Introduction
Skeletal muscle strength and mass are aspects of health and fitness that play
important roles in establishing a person’s performance capabilities as well as quality of
life. Strength training has been widely documented as resulting in increased muscle
strength and hypertrophy. Studies have shown that dynamic strength training (ST) is
effective in increasing both skeletal muscle strength and mass in both males and females
across the adult age span (53, 117, 165, 281, 285, 314).
Studies have also shown substantial variation among subjects for the adaptation of
muscle strength and mass to ST (64, 122, 128, 130, 154), which indicates the potential for
a genetic component to ST-induced muscle adaptation. In general, muscle strength and
mass are known to be heritable phenotypes. Heritability studies have found skeletal
muscle strength to be 14%-80% heritable depending on the muscle group being studied
(10, 170, 243, 294, 301, 315, 375) and the type, speed and angle of muscle contraction
being measured (300). Similarly, skeletal muscle mass has been shown to be 25%-95%
heritable, with the wide range of values being explained by the method of measurement
used to calculate muscle mass (9, 26, 161, 263, 299). Finally, a limited number of studies
have shown that the adaptation of muscle phenotypes to ST also appears to have a genetic
component (288, 293). One study in particular by Thomis et al (292), concluded that
strength training-related genetic factors were responsible for approximately 20% of the
variation found in response of 1RM and isometric strength measurements to strength
training. These studies indicate the importance of genetic influences on muscle strength
and mass, as well as the adaptation to strength training.
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Despite evidence of the importance of genetic factors, few specific candidate
genes have been identified as being important to the response of muscle phenotypes to ST
(226). One gene that has emerged recently as a candidate is angiotensin-converting
enzyme (ACE). An insertion/deletion polymorphism in this gene has been found to be a
marker of activity for this enzyme, with those who carry the deletion (D) allele having
higher ACE enzyme activity (46). Studies have found that homozygotes for the I allele
(II) have significantly less ACE activity than heterozygotes (ID), with heterozygotes (ID)
having lower ACE activity than homozygotes for the D allele (DD) (321, 358). Studies
have concluded that ACE genotype is responsible for half of the variation in ACE activity
(252, 369).
Skeletal muscle has substantial ACE activity, owing to a local renin-angiotensin
system (RAS) (246). Investigators have linked angiotensin II, generated by ACE as the
end product of the RAS, to overload-induced cardiac hypertrophy (193, 257, 276) and
smooth muscle hypertrophy (23, 101). Gordon et al (109) concluded that ACE inhibitors
significantly reduced hypertrophy in overloaded muscles, indicating a role for
angiotensin II in skeletal muscle hypertrophy. These findings were supported in a later
study by Westerkamp and Gordon (344), in which ACE inhibition attenuated overload-
induced increases in muscle weight, muscle protein content and fiber cross-sectional area,
each of which were increased in control animals. McBride (183) found that blocking
angiotensin II’s AT1 receptor attenuated eccentric training-induced hypertrophy and
strength gains in Sprague-Dawley rats. These studies provide evidence of the potential
importance of the RAS and ACE in particular to skeletal muscle hypertrophy in response
to overload.
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Studies investigating the effects of ACE genotype on skeletal muscle strength and
mass in response to strength training have yielded inconsistent results. Folland et al (82)
and Williams et al (357) reported positive associations between the D allele and muscle
strength. Moreover, Folland et al (81) showed a gene*training interaction between ACE
genotype and ST, such that carriers of the D allele (DD + ID) had greater increases in
isometric strength compared to those who were homozygous for the I allele (II). In
contrast, Williams et al (356) showed the D-allele carriers to be stronger at baseline, but
failed to show a gene*training interaction. More recently, Pescatello et al (215) and
Thomis et al (307) failed to support the correlation between the D allele and muscle
adaptation to ST. Pescatello et al (217) concluded that subjects with the I allele had
greater gains in maximum voluntary contraction in both the trained and untrained arms.
This study also concluded that ACE genotype was not related to baseline measures of
strength or size (214). Finally, Thomis et al (306) concluded that ACE genotype had no
effect on 1RM strength response to 10 weeks of ST.
Given the data indicating a possible role for ACE in muscle overload-induced
hypertrophy and the findings of some studies that ACE genotype is associated with
muscle phenotypes, the purpose of this study was to investigate the association between
ACE genotype and skeletal muscle strength and mass, and their adaptation to strength
training in older men and women. Previous investigations have not studied these
associations in females or in different race groups. The inconsistencies in the literature
may also be due to insufficient sample size and/or measurement techniques, particularly
in evaluating muscle size. The current study is a large-scale ST intervention using
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careful measures of muscle size and strength designed to more fully test the possible
association between ACE genotype and muscle phenotypes.
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Hypotheses
Hypothesis 1: ACE genotype will not be correlated with baseline muscle strength
or volume regardless of sex or race.
Rationale: Hypothesis 1 was based on the findings of Folland et al (84) and
Pescatello et al (222) who independently found no baseline association between muscle
strength and ACE genotype, as well as on the findings of Pescatello et al (223) and
Thomis et al (305) who found no correlation between ACE genotype and muscle cross-
sectional area.
Hypothesis 2: Those subjects who are homozygous for the I allele (II genotype)
will have smaller increases in muscle strength and mass in response to strength training
than carriers of the D allele (DD + ID) in all sexes and races.
Rationale: Hypothesis 2 was based on the findings of Folland et al (80), who
presented greater strength improvements in ID and DD genotypes with isometric and
dynamic strength training. Moreover, a biological rationale for greater muscle volume
increases in D allele carriers is provided by studies from Gordon et al (108), Westerkamp
and Gordon (343), and McBride (182), who collectively show that angiotensin II is
required for overload-induced muscle hypertrophy to occur.
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Methods
Subjects: The subjects consisted of 261 previously inactive, relatively healthy
volunteers between the ages of 50 and 85 years old. Volunteers were recruited through a
variety of sources including mailed brochures, newspaper articles and word of mouth
from subjects involved in the study. Prior to acceptance into the study, volunteers were
exposed to a rigorous screening procedure. This procedure included a phone interview, a
medical clearance form to be completed by their primary care physician and an in depth
medical history. In order to be considered for the study, volunteers must have been
sedentary, as operationally defined as a person who performs less than 20 minutes of
vigorous activity per week. Participants in the study were required to be nonsmokers and
completely void of significant cardiovascular, metabolic and musculoskeletal maladies
that could in any way limit their ability to perform heavy resistance training. Subjects
who were already taking medications for more than 3 weeks were included into the study
with the understanding that they would maintain the same medicine and dosage for the
entirety of the study. After all methods and procedures were explained, volunteers who
chose to participate were required to read and sign a written consent form that had been
previously approved by the Institutional Review Board of the University of Maryland,
College Park. Throughout the study, subjects were continually reminded not to alter their
physical activity levels or habitual dietary intake and body weight was measured weekly
to confirm the absence of weight loss or gain.
Strength Testing: One repetition maximum strength tests (1RM) were performed
on both legs separately prior to and at the completion of the strength training
intervention. These tests were performed on the same air powered resistance machines
7
(Keiser Sports/Health Equipment, Fresno, CA) that were used during the training, and
assessed knee extension strength. This exercise could be tested using objective criteria
and therefore provided a standardized measure of each subject’s strength. These
objective criteria involved a light system to indicate a successful attempt when the knee
was extended beyond 165 degrees. The 1RM was defined as the maximum resistance that
could be moved throughout the full range of motion with proper form one time.
Approximately the same number of trials (6-8) and the same amount of rest between
trials (about 1 minute) were used to obtain the 1RM both at baseline and post-training.
Prior to the baseline test, each subject underwent three familiarization sessions with low
resistance and was counseled on proper exercise technique, as well as stretching and an
appropriate warm up. These familiarizations served to validate the measured 1RM by
preventing the large gains that tend to occur as the subjects learn the testing procedure.
They also helped to prevent injuries and muscle soreness in the subjects. Each test was
conducted with consistent seat height, body positioning, verbal commands and
encouragement. Before each test, the subject rested for 5 minutes and then resting blood
pressure was measured. This measurement was followed up with a 1 minute warm up on
a cycle ergometer. All subjects wore a seat belt pulled snugly across the pelvis to avoid
the recruitment of muscle groups outside of the quadriceps. The 1RM measurement was
achieved by gradually increasing the resistance after each successful lift until a maximal
load was reached. Following each attempt, the subject was asked to quantify any pain or
discomfort they experienced during the lift and to provide the tester with a numerical
rating of perceived exertion using the Borg scale.
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Muscle Volume Testing: Quadriceps muscle volume was measured on both the
trained and untrained thighs at baseline and after ten weeks of unilateral training using
computed tomography imaging (CT). Measurements of the untrained leg were taken to
account for seasonal and biological variation in muscle volume. Axial sections of each
thigh were obtained between the most distal point of the ischial tuberosity and the most
proximal boundary of the patella while the subject was placed in the supine position.
Each slice was set at 10mm and slices were separated by 40 mm. This protocol was
based on previous work done in our lab by Tracy et al (322). Quadriceps muscle volume
was estimated using a 4cm interval between the center of each section. Each CT image
was obtained at 120kVp with the scanning time set at 1s at 40mA. A 48cm field of view
and 512 x 512 matrix was used to obtain a pixel resolution of 0.94mm.
For each section of the thigh, cross-sectional area of the quadriceps muscle group
was manually outlined. This manual outlining was done on every section starting from
the border of the proximal patella and ending when the quadriceps are no longer
distinguishable from the hip flexor and adductor muscle groups. The same number of
sections were measured at baseline and post-training for each subject to ensure within
subject replication. Investigators were blinded to the identity to the subject, date of scan
and training status.
Strength Training Intervention: The strength training intervention consisted of
approximately 10 weeks of unilateral (one-legged) knee extensions on the dominant leg.
The exercise was performed on the same Keiser air powered resistance machines that
were used for the 1RM testing. This machine allows for the easy changing of resistance
without interrupting the cadence of the exercise. The untrained leg served as an internal
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control for each subject and therefore remained in a relaxed position for the entirety of
the training program.
Before each exercise session, the subjects rested for 5 minutes and then resting
blood pressure was measured. Any subject whose blood pressure was abnormally
elevated was not permitted to train on that day. Once the blood pressure had been
measured, the subject warmed up for about 2 minutes on a cycle ergometer. They were
then seated in a chair with a seat belt tightly secured across the pelvis to isolate the
quadriceps muscle. Seat positioning in the chair was based on the body dimensions of
the subject and was uniform for each training session. The training protocol included 5
sets of unilateral knee extensions for those under 75 years of age and 4 sets for those 75
and older. The decreased workload for the older subjects was an effort to avoid
overtraining. The first set served as a specific warm up and consisted of 5 repetitions at
50% of the previously determined 1RM. This resistance did not change throughout the
course of the training. The second set, or the first working set, consisted of 5 repetitions
at the current 5 repetition maximum (5RM). The 5RM was initially estimated based on
previous data showing that it corresponds with around 85% of 1RM in most people (120).
The 5RM value was increased throughout the training program to account for increases in
strength. The third set, or second working set, began with the subject doing repetitions at
the 5RM once again. Once they were unable to complete full repetitions (usually around
repetition 4-5), the resistance was decreased just enough to allow them to complete one
or two more repetitions before once again failing to do a complete repetition. This
process continued until 10 repetitions had been completed. This same procedure was
continued for the fourth and fifth sets, but the total number of repetitions completed was
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increased to 15 and 20 repetitions respectively. This protocol required near maximal
effort on every repetition, while still allowing for a high volume of training. The second,
third, fourth, and fifth sets were preceded by rest periods of 30, 90, 150, and 180 seconds
respectively. Each repetition was comprised of a muscle shortening phase lasting
approximately 2 seconds and a muscle lengthening phase of around 3 seconds. The same
light system that was used to signal a complete repetition during the 1RM test was also
used during training to indicate full range of motion for each repetition. Throughout each
set, subjects were provided with verbal motivation and feedback by the investigators.
This verbal communication included audible counting of repetitions, reminders to
continue breathing normally during the exercise and cues to maintain full range of motion
and continue lifting until the light was illuminated. For those subjects who were 75 years
or older, the fourth set of 15 repetitions served as their final set. Immediately after the
completion of the 20th repetition in the final set (or 15th for those in the older group), peak
blood pressure was measured while the subjects remained in the exercise chair.
Following the peak blood pressure measurement, subjects performed supervised stretches
of the quadriceps, hamstrings, calves and hip flexors. They then sat and rested/recovered
for 3 minutes before a final post-exercise blood pressure was measured.
Genotyping: Blood samples were obtained from each subject’s antecubital vein
prior to the strength training intervention using standard, sterile techniques. DNA was
extracted from whole blood samples using standard procedures (Gentra PureGene
System). The ACE I/D polymorphism was genotyped using a polymerase chain reaction
(PCR)-based DNA amplification using flanking primers. The sense primer sequence was
5' CTGGAGACCACTCCCATCCTTTTCT 3' and the antisense primer was 5'
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GATGTGGCCATCACATTCGTCAGAT 3'. The PCR product was a 190 base pair
fragment for the deletion (D) genotype and a 490 base pair fragment for the insertion (I)
genotype (247). Genotyping was performed by separating the PCR amplicon on a 2%
agarose gel with ethidium bromide staining (325). Positive control samples for each
genotype were obtained through direct DNA sequencing and used to validate all
genotyping assays.
Statistical Analysis: All data for this study were analyzed using SAS computer
software for Windows (version 9.1). Statistical analysis for this investigation used
analysis of covariance (ANCOVA) to compare the means among ACE D-allele carriers
and non-carriers (II genotype vs. ID+DD genotypes). D allele carriers were grouped
together to allow for easy comparison with other studies that performed similar analyses.
Furthermore, analysis of the data across the three genotype groups showed no difference
between ID heterozygotes and DD homozygotes. Covariables included for each measure
of muscle strength and volume are presented in the results section. Men and women were
analyzed separately given known differences in muscle phenotypes. African Americans
and Caucasians were also analyzed separately in sub-analyses. Change in muscle volume
was analyzed after subtracting changes in the untrained thigh using the equation: (Post
Trained Leg – Post Untrained Leg) – (Baseline Trained Leg – Baseline Untrained Leg).
Removing the untrained leg corrected for changes in muscle volume that were not related
to the strength training intervention.
Paired T-tests were performed within ACE D-allele carrier and non-carrier groups
to confirm that the strength training intervention was adequate to affect the muscle
strength and mass phenotypes. Baseline characteristics are presented as least squared
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means ± standard deviation. All other data are presented as least squared means ±
standard error. Statistical significance for all analyses was as accepted at p ≤ 0.05.
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Results
Subject Characteristics: A total of 243 subjects were studied and their characteristics are
shown in Table 1; no significant differences were observed.
Table 1: Subject characteristics by sex & ACE genotype
Men Women
II ID DD II ID DD
N 14 29 48 29 50 73
Age 62.8 ± 8.5 63.8 ± 7.9 62.1 ± 8.7 64.9 ± 8.9 62.2 ± 8.2 61.4 ± 9.3
Hgt 173.5 ± 5.7 173.6 ± 7 175.5 ± 7.8 162 ± 6.3 162.5 ± 5.9 162 ± 6.7
Wgt 80.8 ± 10.4 88.9 ± 11.3 92.6 ± 15.4 73.2 ± 14.9 77.3 ± 15.3 75.7 ± 15.7
FM 22 ± 5 26 ± 6.8 26.4 ± 8.1 29.8 ± 9.9 31.8 ± 9.4 30.5 ± 9.8
FFM 58.8 ± 7.1 62.9 ± 6.5 66 ± 9.2 43.4 ± 6.1 45.5 ± 7.2 45.3 ± 6.8
Data presented as means ± standard deviation. N = Number of subjects, Hgt = Height (cm), Wgt = Weight
(kg), FM = Fat Mass (kg) and FFM = Fat Free Mass (kg).
Table 2 shows the baseline subject characteristics of the two separate genotype
groups (II homozygotes and D allele carriers) that were explored in this investigation,
separated by males and females. There were significant differences found between
genotype groups in the males for baseline weight (kg) (p = 0.02) and fat free mass (kg) (p
= 0.02). There were no significant differences among females for any of the baseline
subject characteristics.
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Table 2: Subject characteristics by sex and ACE genotype group
Males Females
DD + ID II DD + ID II
N 77 14 123 29
Age 62.7 ± 0.95 62.8 ± 2.27 61.7 ± 0.79 64.9 ± 1.65
Height 174.8 ± 0.86 173.5 ± 1.58 162.2 ± 0.58 162 ± 1.18
Weight 91.3 ± 1.63 * 80.8 ± 2.9 * 76.3 ± 1.42 73.2 ± 2.76
FM 26.3 ± 0.89 22 ± 1.38 31 ± 0.88 29.8 ± 1.83
FFM 64.9 ± 0.99 * 58.8 ± 1.96 * 45.4 ± 0.63 43.4 ± 1.13
Data presented as means ± standard error. Investigation groups are II homozygotes and D allele carriers.
Missing data is due to lack of genotype data available. Significant difference between genotype groups are
indicated by a * (p < 0.05). N = Number of subjects, Hgt = Height (cm), Wgt = Weight (kg), FM = Fat
Mass (kg) and FFM = Fat Free Mass (kg).
Table 3 shows the subject characteristics of the separate sex and race groups that
were investigated. The African American males were significantly younger than the
Caucasian males (p = 0.03) and had significantly more fat free mass than Caucasian
males (p = 0.007). The African American females were significantly younger (p =
0.0002), taller (p = 0.003), and heavier (p = 0.03) than the Caucasian females.
Table 3: Subject characteristics by sex and race
Males Females
Caucasian AA Caucasian AA
N 61 25 86 56
Age 64 ± 1.11* 59.8 ± 1.39* 64.4 ± 1.03* 59.1 ± 0.95*
Height (cm) 175.1 ± 0.91 174.4 ± 1.57 161.6 ± 0.7* 164.4 ± 0.61*
Weight (kg) 87.6 ± 1.76 93.5 ± 3.09 74.4 ± 1.77* 80.1 ± 1.81*
FM (kg) 25.1 ± 0.96 25.7 ± 1.55 30.4 ± 1.12 32.3 ± 1.21
FFM (kg) 62.3 ± 1.06* 67.8 ± 1.84* 44 ± 0.75 47.9 ± 0.75
Data presented as means ± standard error. Investigation groups are II homozygotes and D allele carriers.
Significant difference between genotype groups are indicated by a * (p < 0.05). N = Number of subjects,
Hgt = Height (cm), Wgt = Weight (kg), FM = Fat Mass (kg) and FFM = Fat Free Mass (kg).
15
Genotype Frequency: Table 4 shows the genotype and allele frequencies for all
subjects. Of the 243 total subjects involved in the analysis, there were 43 II
homozygotes, 79 ID heterozygotes, and 121 DD homozygotes. For analytical purposes,
this equated to 43 II homozygotes and 200 D allele carriers. Genotype frequency was
further investigated based on race. Our study included 147 Caucasians and 81 African
Americans. The Caucasian group included 30, 44, and 73 II, ID and DD genotypes
respectively, which equated to 30 II homozygotes versus 117 D allele carriers. The
African American group included 13, 27, and 41 II, ID and DD genotypes respectively,
which equated to 13 II homozygotes versus 68 D allele carriers.
Table 4: ACE genotype & allele frequencies by race
II ID DD I allele D allele
Total (%) 43 (17.7%) 79 (32.5%) 121 (49.8%) 34% 66%
Caucasian 30 (20.4%) 44 (29.9%) 73 (49.7%) 35.4% 64.6%
African
American
13 (16.1%) 27 (33.3%) 41 (50.6%) 32.7% 67.3%
Of the 13 African Americans who were II homozygotes, only one was male. This
small number of subjects within this genotype group was insufficient to perform any
meaningful analysis and therefore the comparisons of muscle phenotypes between
African American males who carry the D allele and African American II homozygotes
were not used to draw any conclusions.
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Muscle Strength: Analysis of the entire cohort by genotype group resulted in no
significant differences for 1RM strength at baseline (p = 0.13), post training (p = 0.13), or
change with training (p = 0.68; data not shown). No significant differences were
observed for muscle strength between genotype groups in either males or females at any
point of analysis (Table 5). Analysis of strength measures included covarying for age,
height and muscle volume. At baseline, statistical analysis yielded no significant
difference in either males (p = 0.18) or females (p = 0.52). Similarly, there was also no
significant difference in 1RM between genotype groups after strength training in males (p
= 0.42) or females (p = 0.15). Finally, there was no significant gene*training interaction
between ACE genotype and strength training. This lack of interaction resulted in no
significant difference in change in 1RM with training between the groups in either males
(p = 0.52) or females (p = 0.77). Analyses excluding muscle volume as a covariate
similarly yielded no significant differences (data not shown). Strength analysis of the
entire cohort by genotype (II vs. ID vs. DD) yielded no significant differences for
baseline 1RM (p = 0.24), post training 1RM (p = 0.31) and change in 1RM (p = 0.64).
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24.19 ± .85 0.15
∆ 1RM 8.25 ± 0.57 7.33 ± 1.31 0.52 5.04 ± 0.34 5.26 ± 0.65 0.77
Data presented as least squares means ± SE. 1RM values are presented in kg.
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Muscle Volume: Analysis of the entire cohort showed no significant differences
for muscle volume at baseline (p = 0.06), post training (p = 0.6) or change with training
(p = 0.31; data not shown). There were no statistically significant differences between
the genotype groups for any of the muscle volume measures in either sex group (Table 6). 
Covariables for the analysis of muscle volume were age and height. At baseline, there
was no significant difference in muscle volume in females (p = 0.27), though male D-
allele carriers tended to have higher muscle volume levels than the II group (p = 0.07).
Post training muscle volume also lacked a significant difference between genotype
groups in males (p = 0.11) and females (p = 0.88). Finally, there was also no significant
difference between groups in change in muscle volume with training in either males (p =
0.47) or females (p = 0.77). Muscle volume analysis of the entire cohort by genotype (II
vs. ID vs. DD) yielded no significant differences for baseline muscle volume (p = 0.07),
post training muscle volume (p = 0.52) and change in muscle volume (p = 0.92).
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Data presented as least squares means ± SE. Muscle Volume values are in cm3.
Muscle Strength by Race: Tables 7 and 8 show the strength differences between
genotype groups separated by race and sex. Baseline 1RM was not significantly different
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between D allele carriers and II homozygotes in either Caucasian males (p = 0.59) or
Caucasian females (p = 0.77). Post training 1RM was also not significantly different
between genotype groups in Caucasian males (p = 0.70) and females (p = 0.44). Change
in 1RM was also not significantly different between the genotype groups in either the
Caucasian males (p = 0.89) or Caucasian females (p = 0.31). In African Americans
baseline 1RM (p = 0.42), post training 1RM (p = 0.32) and change with training (p =
0.35) were not significantly different between genotype groups in African American
females. Once again, the covariables for these statistical analyses were age, height, and
muscle volume. Conclusions about African American males could not be drawn do to a
lack of II homozygotes in this group.
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∆ 1RM 7.70 ± 0.52 7.53 ± 1.02 0.89 10.67 ± 0.8 -0.31 0.19
Data presented as least squares means ± SE. 1RM values are presented in kg.
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∆ 1RM 4.77 ± 0.40 5.69 ± .81 0.31 6.14 ± 0.74 4.73 ± 1.25 0.35
Data presented as least squares means ± SE. 1RM values are presented in kg. Significant difference
between genotype groups are indicated by a * (p < 0.05).
Muscle Volume by Race: Baseline muscle volume was not significantly different
between the genotype groups in Caucasian males (p = 0.24), Caucasian females (p =
0.20), or African American females (p = 0.26; Tables 9 and 10). Similarly, post training
muscle volume was not significantly different between genotype groups in Caucasian
males (p = 0.30), Caucasian females (p = 0.90), or African American females (p = 0.46).
Change in muscle volume with strength training was significantly different in Caucasian
males (p = 0.02) with the D allele carriers demonstrating greater hypertrophy with
training than II homozygotes. This difference was not observed in Caucasian females (p =
0.77), or African American females (p = 0.71). All of the statistical analyses performed
on the muscle volume data were covaried for age and height. Once again, the number of
II homozygotes among African American males was inadequate to draw any conclusions
about this group.
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Data presented as least squares means ± SE. Muscle Volume values are in cm3. Significant difference
between genotype groups are indicated by a * (p < 0.05).
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Data presented as least squares means ± SE. Muscle Volume values are in cm3. Significant difference
between genotype groups are indicated by a * (p < 0.05).
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Discussion
The results of this investigation indicate no clear association of the ACE I/D
genotype with skeletal muscle strength before or after strength training in older adults.
The results do provide evidence of a minor association between ACE genotype and
muscle volume in males, possibly limited to Caucasian males. Based on previous studies,
we had hypothesized that the D allele of the ACE gene would not be associated with
baseline measures of skeletal muscle strength or muscle volume. This hypothesis was
partially supported, in that baseline muscle strength was not associated with ACE
genotype. However, this investigation revealed a tendency for male carriers of the D
allele to have greater baseline muscle volume than II homozygotes. The second
hypothesis was that carriers of the D allele would exhibit greater increases in muscle
strength and volume after strength training compared to the II genotype group. Once
again, this hypothesis was only partially upheld by the data, in that Caucasian males who
carried at least one D allele exhibited significantly more hypertrophy than II
homozygotes. When considered within the context of previous studies, the present
investigation suggests that ACE genotype play a minor role in skeletal muscle size and its
adaptation to strength training, but potentially only in certain subgroups within the
population.
The lack of association between ACE genotype and baseline strength reported
here supports earlier findings by both Folland et al (79) and Pescatello et al (213). These
previous studies concluded that baseline isokinetic, isometric, and isotonic muscle
strength were not associated with ACE genotype in either the upper arm (212) or the leg
(78). In contrast, Williams et al (355) reported a significant association between ACE
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genotype and pretraining isometric and isokinetic strength in the knee extensors.
Specifically, this study concluded that those with the most circulating ACE, DD
homozygotes, were the strongest, whereas those with lower ACE levels, II homozygotes,
were the weakest (354).
The lack of gene*training interaction affecting muscle strength was contrary to
our a priori hypothesis. Folland et al (85) tested the interaction of ACE genotype with
isometric strength training as well as the interaction of ACE genotype with isotonic
strength training. Subjects in this study performed isometric strength training on one leg
and isotonic strength training on the other leg. Strength was then tested using both
isometric and isokinetic knee extension tests. The authors found that the response to
isometric strength training was strongly associated with ACE genotype and that the
carriers of at least one D allele experienced significantly greater strength increases than II
homozygotes. They also found a similar, but non-significant, tendency for the response
of isometric strength to isotonic strength training to be greater in the D allele carriers vs.
the II genotype group (77). The authors explained this non-significant strength gain on
less uniformity and duration of loading during the isotonic training (76). However it
seems likely that some strength gain was masked by a disconnect between the isotonic
training stimulus and the isometric strength testing. Pescatello et al’s (211) study of
upper arm strength reported a gene*training interaction that was different than the one
found by Folland et al: greater increases in maximal voluntary contraction with training
in carriers of the I allele than in DD homozygotes. Pescatello et al also observed that
biceps 1RM increased more in the carriers of the D allele when testing the untrained arm,
indicating a potential gene*training interaction that is involved with muscle cross-
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education (210). These two previous studies thus present conflicting results regarding the
nature of a gene*training interaction that links ACE genotype with strength training,
though the findings of Folland et al are more consistent with the biological rationale for
ACE genotype. The results of the present study did not support any of the findings of
these studies, in that we failed to observe a significant difference in increases of dynamic
muscle strength with strength training between D allele carriers and II homozygotes.
Furthermore, our data revealed no significant difference between groups regarding
muscle strength both when muscle volume was and was not corrected for as a covariate.
The present investigation observed a tendency for males who carried the D allele
to have greater baseline muscle volume. Although these results did not reach statistical
significance, they were in line with our hypothesis that the D allele would provide an
advantage in tests of muscle size and may represent an important association. It was also
observed that Caucasian males who carried the D allele had a greater hypertrophic
response to strength training than the Caucasian males who were II homozygotes.
Previous studies that have investigated the association of ACE genotype with the muscle
size response to strength training have also concluded that there is no association (209,
304). However, both of these studies used muscle cross-sectional area to assess muscle
size. In the present investigation, muscle size was assessed using muscle volume which
is a more effective technique in that it measures the size of the entire muscle rather than
relying on a representative slice (255).
The likely mechanism through which ACE genotype affects skeletal muscle size
is through production of angiotensin II. ACE is responsible for producing angiotensin II,
which acts as a growth factor in cardiac (186, 260) and smooth muscle cells (22, 102).
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Montgomery et al (190) showed left ventricular hypertrophy in response to exercise was
greater in carriers of the D allele compared to II homozygotes. This indicates a potential
interaction between exercise-induced overload and ACE genotype that affects muscle
hypertrophy. As discussed previously, the presence of a local RAS in skeletal muscle and
the consistent association of the D-allele with higher ACE levels provides a rationale for
the hypothesis that ACE genotype may influence angiotensin II levels in skeletal muscle.
Further biological support for a potential gene*training interaction comes from studies
that have shown an interaction between angiotensin II and overload-induced skeletal
muscle hypertrophy in animal models (107, 342). These studies found that decreased
levels of angiotensin II, resulting from ACE inhibition, effectively attenuated skeletal
muscle hypertrophy that normally occurred under overload (106, 341). Another study
has shown that blocking the AT1 receptors, through which angiotensin II signals muscle
cells, can attenuate exercise-induced skeletal muscle hypertrophy (181). These studies
provide a biological rationale for explaining a potential role for ACE genotype in
affecting muscle size. In these animal studies, ACE inhibition was used to decrease the
production of angiotensin II through the renin-angiotensin system. Similarly, in people
who are II homozygotes for the ACE gene, the conversion of angiotensin I into
angiotensin II is lower than in those who carry the D allele (35). Therefore, these studies
provide support for the hypothesis that II homozygotes would have an attenuated
hypertrophic response to overload, much like the animal models injected with ACE
inhibitors. In the current study, Caucasian male carriers of the D allele demonstrated
greater overload-induced hypertrophy compared to II genotype carriers, consistent with
expectations derived from these studies. The effect of ACE on skeletal muscle size has
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been disputed in the literature. Some previous studies have found that ACE inhibition
resulted in reduced muscle atrophy rather than being associated with decreased muscle
size as would be expected from the work described above (31, 268, 280). However, these
studies were commonly performed on diseased subjects. It is possible that in these
populations ACE inhibitors allowed subjects to better tolerate physical activity which
could act to decrease muscle wasting caused by a sedentary lifestyle (49).
The results of the present study as well as those that have previously studied ACE
genotype and strength training indicate that the ACE I/D genotype is not a major
determinant of skeletal muscle strength or size or their response to strength training, but it
may play a minor role in some sub-groups. It is possible that the influence of ACE
genotype is only observed in males, and perhaps may be further limited to Caucasian
males, though sample size limitations in the present study preclude strong conclusions in
this regard. Folland et al (75) showed a gene*training interaction regarding muscle
strength in a cohort of Caucasian males. Similarly the only significant finding of the
current study, increased hypertrophy among D allele carriers, was also limited to
Caucasian males. Given the inconclusive nature of the results of various studies, it seems
unlikely that ACE I/D genotype is more than just a minor contributor in the determination
of skeletal muscle strength and size response to training.
To the best of our knowledge, this investigation is the first large-scale study of the
association between ACE genotype and skeletal muscle strength and size using muscles
in the lower body. The two previous studies that investigated this association in the knee
extensors only had 33 and 44 subjects, respectively, who completed the training protocol
(74, 353). The current investigation is also the first to study these associations in an
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older population. All of the prior studies that investigated ACE genotype and strength
training involved subjects who were 30 years old or younger (73, 216, 312, 352). Finally,
other than the study by Pescatello et al (208), no previous study examined females or
racial minorities (72, 303, 360) and Pescatello et al did not report separate analyses for
sex- or race-based subgroups. Thus, to the best of our knowledge, the current study is the
first to perform separate gender and race based analyses of the effect of ACE genotype on
skeletal muscle strength and muscle volume.
ACE genotype frequencies have been shown to differ among race groups (17, 20,
173). Commonly, the allele frequency among Caucasians for this insertion/deletion
polymorphism is approximately 50% for both the I and D alleles compared to 41% I
alleles and 59% D alleles in African Americans (172). However, in the present study, the
allele frequency of the Caucasian subjects was 35% for the I allele and 65% for the D
allele. The African American subjects had an allele frequency of 32.7% for the I allele
and 67.3% for the D allele, which was much closer to the expected distribution within
this population. The atypical genotype distribution among Caucasian subjects and the
typical distribution among African Americans resulted in the total group having allele
frequencies that were high for the D allele (34% I allele and 66% D allele frequencies).
We are uncertain why our subject group had this abnormal allele frequency. Our
genotyping protocol has been validated and is a commonly accepted and utilized
protocol. However, it seems unlikely that this atypical allele distribution among the
Caucasian subjects were relevant to our results. The statistical analysis between
genotype groups within Caucasians resulted in p-values that did not approach
significance in any measures of muscle strength or size except for change in muscle
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volume in Caucasian males. It seems unlikely that the increased number of D allele
carriers were able to cause such a high level of non-significance.
The main limitation of this study was the inability to draw conclusions about
African American males. This population subgroup had to be removed from the analysis
due to an insufficient number of II homozygotes among that group. This limitation
hinders our ability to conclude if the ACE gene is associated with muscle strength and
size in all males or only in Caucasian males. Further limitations were that subjects were
responsible for maintaining their habitual dietary intake and remain sedentary throughout
the entire study. It is possible that some subjects may have unknowingly altered these
variables.
In summary, the present study observed no clear association between ACE
genotype and baseline or post training skeletal muscle strength in untrained older adults.
The present study did show an association between ACE genotype and skeletal muscle
volume adaptations as a result of strength training in Caucasian males, with carriers of
the D allele having greater muscle hypertrophy than the II homozygotes. There was also
a tendency among all male subjects for the D allele carriers to have greater baseline
muscle volume than their II counterparts. However when subjects were divided by race,
this association at baseline no longer approached significance. These results are
generally supportive of animal studies that have shown ACE inhibition to attenuate
hypertrophic response in the face of muscle overload. Further research needs to be done
to investigate this association in other male populations, particularly African Americans
who typically have a higher frequency of D allele carriers but were lacking in the present
investigation. There should also be further investigation into the association of ACE
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genotype with baseline muscle volume in males that approached significance in the
present study. Our results, in combination with those of others, do provide evidence that
at most the ACE I/D genotype is contributing only a small fraction of the variation in
muscle phenotypes. Further research is clearly necessary to identify and investigate other
candidate genes that may be important in determining muscle strength and size and their
response to strength training.
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Conclusions
Conclusion 1: It was hypothesized that ACE genotype would not be correlated
with either baseline muscle strength or baseline muscle volume. Our data indicated no
significant difference between ACE genotype groups regarding muscle strength and
muscle volume. Therefore, this hypothesis was supported by our data. However, there
was a tendency that approached significance for males who carry the D allele to have
greater baseline muscle volume than II homozygote males.
Conclusion 2: The second hypothesis that we investigated was that II
homozygotes would have smaller increases in muscle strength and volume after the
completion of a strength training intervention compared to D allele carriers. Instead, the
data indicated that there was no difference in strength increases with strength training
between ACE genotype groups. Furthermore, most groups showed no significant
difference in muscle volume increases with strength training between ACE genotype
groups. However, there was a significant difference in change in muscle volume among
Caucasian males that was supportive of our hypothesis. Therefore, this hypothesis was
partially supported by our data.
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Appendix A – Limitations of Study
Delimitations:
1. The scope of the race analysis of this study was delimited to 147 Caucasians and
81 African Americans and the scope of the sex analysis was delimited to 91 males
and 152 females. The subjects were further delimited to people between the ages
of 50 and 85 years.
2. Participation in the study was delimited to healthy participants free of
musculoskeletal or cardiovascular disease and maintained a level of independence
that allowed them to attend training sessions at our facility three times per week.
3. Subjects were delimited to volunteers who lived within 20 minutes of the
training/testing facility and responded to mailed advertisements.
Limitations:
1. This study is limited to drawing conclusions about the population from which the
subjects were selected. This population includes older adult males and females
characterized by two racial groups, African Americans and Caucasians. The
ability to generalize our conclusions is further limited to people of similar age,
health status, level of physical activity and motivational status as our subjects.
2. Subjects self-reported physical activity level, dietary habits, medication intake
and medical conditions. Some of these factors may have been under-reported.
However, with the large sample size of this study it is unlikely that any errors in
these self reports would significantly affect our results.
3. Subjects were asked to maintain their dietary intake and refrain from increased
physical activity outside of the strength training intervention that this study
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provided. Some subjects may have unknowingly altered one or both of these
variables. Once again however, with the large sample size of this study, it is
unlikely that any changes in physical activity or nutritional intake would
significantly affect our results.
4. Another potential limitation of this study is the abnormal distribution of ACE I/D
genotype frequencies among the Caucasians in our subject group. Our subjects
included many more carriers of the D allele than would be expected based on
previous literature. We are confident that this uncommon genotype distribution
occurred within this subject pool and was not caused by error during the
genotyping process. Prior to genotyping subject samples, sequence-verified
control samples were performed to ensure the accuracy of the genotyping
methods employed during this study. This atypical distribution may have masked
an association between ACE genotype and the phenotypes being investigated.
5. Finally, the division of the subject pool by race and sex may have caused some of
the analyses to lose some statistical power.
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Appendix B – Abbreviations
1RM – 1 Repetition Maximum
ACE – Angiotensin Converting Enzyme
ACE I/D – Angiotensin Converting Enzyme Insertion/Deletion Polymorphism
Ang II – Angiotensin II
cc3 – Cubic Centimeters
CT – Computed Tomography
DD – Homozygotes with 2 deletion alleles
ID – Heterozygotes with 1 insertion allele and 1 deletion allele
ID + DD – ID Heterozygotes and DD Homozygotes joined into one group
II – Homozygotes with 2 insertion alleles
kg – Kilograms
PCR – Polymerase Chain Reaction
ST – Strength Training
TL – Trained Leg
UL – Untrained Leg
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Appendix C – Statistical Power
The statistical power calculations for this project were based on the number of
subjects for whom muscle phenotype data and DNA samples exist. The effect size for
differences in muscle strength was set at 2.37 kg in 1RM. This effect size represents
~12% of the typical 1RM measurements reported in other studies who tested subjects
similar to ours (142, 145, 150). The standard deviation for this measurement was 7.02
based on the same prior studies (141, 145, 149). We chose 12% of typical 1RM values as
the effect size based on several studies that have reported that after the age of 50 yr.,
people lose an average of 12-14% of their muscle strength per decade (153, 156, 166,
187). Therefore, this 12% difference is the average loss in muscle strength per decade
that has been found in most people. As can be seen in Table C1, this project will have a
power of 96.6% when using 2.37 kg as the effect size to test the 252 subjects for whom
baseline 1RM data exist. The power to test the gene*training interaction will be 90.4%
when analyzing the data of the 188 subjects who completed all aspects of the training
program. The alpha level for both of these tests was set at 0.05.
Table C1 – Muscle strength statistical power calculations.
Analysis Alpha Subjects Power
Baseline Strength 0.05 252 96.6%
Change in Strength 0.05 188 90.4%
The effect size for muscle volume was set at a difference of 52.5 cm3, which
represents ~5% of the muscle volume values reported in two studies by Tesch et al (286,
287) and a study by Reeves et al (244). The standard deviation for this measure was 71.1
based on the findings of studies by Reeves et al (244), Tesch et al (286, 287) and a
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previous study from our lab (143). A longitudinal study by Frontera et al (87) concluded
that after 12 years, subjects had lost 12.5-16.1% or a little over 1% per year. Two studies
by Visser et al (335, 336) concluded that a 5% change in muscle volume is functionally
significant. Therefore, the 5% effect size for this study is physiologically significant as
well as roughly translating to the amount of change that could occur in half a decade in
the later stages of adult life. By employing an effect size of 52.5 cm3 this project will
have a power of 99% for both the baseline analysis (232 subjects) and the analysis of the
training effect (180 subjects). The alpha level for both of these tests was set at 0.05
(Table C2).
Table C2 – Muscle volume statistical power calculations




Change in Volume 0.05 180 99%
Tables C3 and C4 present the statistical power for each analysis that was
performed as part of the present study. The effect sizes and standard deviations were the
same as those described above.
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Table C3: Muscle strength statistical power calculations by sex and race
Alpha Subjects Power
Males 0.05 71 0.62
Females 0.05 92 0.83
Caucasians
Males 0.05 53 0.60
Females 0.05 61 0.46
African Americans
Males 0.05 18 0.22
Females 0.05 31 0.43
Table C4: Muscle volume statistical power calculations by sex and race
Alpha Subjects Power
Males 0.05 69 0.99
Females 0.05 90 0.99
Caucasians
Males 0.05 51 0.96
Females 0.05 59 0.98
African Americans
Males 0.05 18 0.58
Females 0.05 31 0.80
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Appendix D - Review of Literature
This review will begin with a discussion of skeletal muscle and its importance to
physical function. This discussion of physical function will focus on the importance
skeletal muscle has in characterizing and maintaining quality of life and functional
capacity as people age. Along with this discussion of quality of life and functional
capacity will be a brief discussion of sarcopenia. That will be followed by a review of
strength training interventions and their effect on skeletal muscle strength and mass,
including the use of strength training in older populations and its effectiveness as a
treatment for sarcopenia. After a brief section on the variability in the effectiveness of
strength training, this review will move to the heritability of muscle strength, mass, and
strength training responses. From there, the discussion will move to the candidate gene:
angiotensin converting enzyme (ACE). Discussion of this gene will review the
physiology of its involvement in the cardiovascular system and skeletal muscle. The
genetics of the key polymorphism within ACE will then be presented followed by a
review of its relation to cardiovascular phenotypes. Finally, this review will be
completed with a section describing the exercise studies that have been completed
regarding ACE genotype and endurance, sprint, and strength training performance.
Importance of Skeletal Muscle:
Skeletal muscle is an important tissue that serves many functions in the body.
The most obvious of these functions is muscle strength and power and their significant
influence over a person’s ability to perform physical tasks. These physical tasks include
performance in athletic and leisure activities, execution of work related duties, chores
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around the home and anything else that involves movement (e.g., speech, eye movement
and most importantly respiration). Skeletal muscle is also important in metabolism, as
the majority of calories are burned by muscle. Thus, people who have more skeletal
muscle mass maintain a higher metabolic rate. Furthermore, developing strength in the
skeletal muscles in the younger ages tends to promote a healthier lifestyle as a person
ages.
Quality of Life/Functional Capacity: Skeletal muscle strength and mass are
important in maintaining functional capacity and thus quality of life, especially in older
adults. Studies have concluded that the decline of muscle strength with age is an
important risk factor of increased disability, morbidity and mortality (148, 232).
Muscular strength is also largely responsible for the reduced independence and quality of
life that many elderly adults experience. This diminished quality of life stems from the
decreased walking speed, impaired mobility and increased risk and fear of falls that
comes with a loss of muscle strength (41, 88, 152, 203). A paper by Young stated that
increasing muscle weakness in older adults may lead to the inability to perform everyday
activities like rising from a seated position, which will lead to further inactivity and
deterioration of functional status (373). Fiatarone et al (63) showed that in people living
in nursing homes, time required to stand from a chair was inversely correlated with
dominant quadriceps strength. This same paper also stated that a similar correlation
existed between 6 meter walk time and dominant leg 1-repetition maximum (1RM)
strength (62). Visser et al (337) showed that leg muscle mass was inversely related with
lower extremity performance in older adults. They also concluded that leg muscle
strength is directly associated with lower extremity performance. A study by Lamoureux
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et al (147) tested the effect of lower body strength on performance in a walking obstacle
course. They found that knee extensor strength could predict performance of 15 gait
variables and that the importance of muscle strength increased as the gait obstructions
became more challenging. These findings led Lamoureux et al to draw the conclusion
that enhanced lower body strength through resistance training could aid older people in
maintaining their functional mobility and thus independence (146). A study by
Schenkman et al (272) investigated the importance of muscle strength and balance in the
completion of a series of chair rise tests. They concluded that successfully rising from a
seated position was most significantly predicted by lower body muscle strength (273). A
study by Rantanen et al (234) concluded that older adults with lower levels of muscle
strength had more difficulty with motor tasks. They also reported that within groups with
similar activity levels, lower levels of muscle strength were associated with more
difficulty completing functional tasks (235).
Sarcopenia, which is defined as the age related reduction in muscle mass, has
been translated into the main reason for the lack of skeletal muscle strength that
characterizes the majority of older people (33, 89, 177, 240). Muscle strength commonly
reaches its peak between the ages of 25 and 35 years, is maintained during the fifth
decade and then begins to decline at a pace of approximately 12-14% per decade starting
at age 50 yr. (151, 157, 168, 187). Despite some evidence that intrinsic muscle factors
are reduced with advanced age, the strength loss that occurs after the age of 50 years is
highly correlated with this age-related loss of muscle mass (90, 137, 167, 176, 239). The
consequences of sarcopenia can be numerous and extensive. They may include increased
susceptibility to falls, increased likelihood of fractures, impairments in thermoregulation,
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reduced metabolic rate, glucose regulation deficiencies and loss of overall functional
capacity and ability to perform everyday tasks (178).
Sarcopenia also increases the risk of mortality both indirectly through the list of
consequences discussed above and directly through decreased muscle mass and strength.
Studies have shown in various populations who experience muscle wasting, that a loss of
more than 40% of baseline lean mass is fatal (144, 282, 364). Baseline is typically
defined as the mean for adults aged 20-30 years old (139). Muscle strength has a greater
correlation with mortality than muscle mass. Rantanen et al (237) found handgrip
strength to be associated with cause-specific and total mortality in older, disabled
females. This study concluded that grip strength is a good predictor of mortality due to
cardiovascular disease, respiratory disease, other diseases (except cancer) and total
mortality. In the case of each of these associations, those with the lowest grip strength
had a significantly higher relative risk of mortality (236). A study by Sasaki et al (270)
supported an association between grip strength and mortality in both sexes and over a
wide age range. This study investigated grip strength in males and females divided into
three age groups (35-54 yrs, 55-64 yrs, and 65-74 yrs) and then followed up on mortality
rate of these subjects for more than 20 years. They found that both males and females
who scored best on the grip strength test had the lowest relative risk for all cause
mortality. This conclusion was true for both the middle and older age groups (269). Grip
strength is believed to be representative of overall muscular strength due to its high
correlation to other strength measures including elbow flexion, knee extension, trunk
flexion and trunk extension (233). Therefore, these studies indicate that muscle strength
is important not only for maintaining quality of life, but also lengthening life in general.
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Thus, the muscle strength that is lost due to sarcopenia increases the risk of death for
older adults.
Strength Training Interventions:
Effects of Strength Training: Strength training has been widely documented as
resulting in increased muscle strength and hypertrophy. Muscle hypertrophy, which is
characterized as greater muscle cross-sectional area, is primarily the result of increased
individual muscle fiber size (54, 116, 313). A study by Haggmark et al (115)
investigated the use of computed tomography in measuring muscle area in subjects
ranging from sedentary to elite athletes. They found that the largest muscle areas
belonged to the heavy weight lifters involved in the study (114). A study by Tesch (283)
found that long-term heavy strength training resulted in increased synthesis of myofiber
proteins. The result of this increase was larger muscle cross-sectional area, mainly
brought about by hypertrophy in the fast twitch muscle fibers (284). A study by Dons et
al (52) studied the effect of dynamic strength training at 80% of 1RM in young males.
They found that this type of training was effective at increasing dynamic muscle strength
as subjects increased strength by 42%. The authors also observed significant muscle
hypertrophy with this type of strength training (51). Similar results have been shown in
females who underwent heavy strength training. A study by Staron et al (281) showed
consistent and significant increases in 1RM throughout 16 weeks of heavy strength
training. This training also resulted in significant decreases in body fat and increases in
muscle mass such that overall thigh circumference remained unchanged (281). Finally, a
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study by Luthi et al (164) found strength training led to increases in strength up to 84% in
the knee extensors, as well as increases in midthigh cross-sectional area.
Clearly, it is well documented that strength training is an effective intervention
for increasing muscle strength and muscle size. Studies have shown that both muscle
strength increases and muscle hypertrophy are achievable in both males and females.
Once these conclusions were drawn, researchers turned to studying strength training in
older adults as a potential method of maintaining function and as a treatment for
sarcopenia.
Older Populations: Many studies have shown that older adults can achieve many
of the benefits of strength training, including increased muscle strength. Hurley et al
(127) showed that older adults are able to perform strength training intense enough to
promote increases in muscle strength and hypertrophy without resulting in significant
muscle damage or soreness. Subjects in this study, underwent 16 weeks of strength
training, which resulted in a 43% increase in total muscle strength (126). A study by
Hakkinen et al (119) showed that elderly men and women, averaging 70 years of age,
were able to increase muscle strength after 6-months of heavy strength training. In this
study, strength increases were exhibited in tests for maximal isometric force as well as
1RM strength. The authors concluded that this increase in strength was caused by neural
improvements, in the form of increases in maximal voluntary activation of the agonist
muscles, and muscular hypertrophy (118). Frontera et al (94) found that dynamic
strength training can increase both 1RM strength as well as isokinetic strength. These
strength improvements were in part due to growth of muscle fibers (93).
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Studies have also shown that muscle size responses to strength training are not
limited by aging. A study by Roth et al (254) reported the effects of 6-months of full
body strength training on muscle volume in a sample of young and old males and
females. They concluded that muscle volume response to this type of strength training
was independent of age and gender (253). Hurley et al (125) showed that full-body,
heavy resistance training can cause muscle hypertrophy in older men. In this study,
strength training yielded a 7.2% increase in midthigh muscle cross-sectional area (124).
A study by Treuth et al (324) showed that strength training can significantly alter body
composition in older males (average 60 yrs). In that study, 16 weeks of strength training
resulted in subjects significantly decreasing fat mass in their arms, legs and trunk as well
as decreasing their overall body fat percentage. These losses in fat mass were countered
with increases in fat free mass in the arms, legs and trunk, such that total body weight
remained unchanged. Magnetic resonance imaging was used to confirm that these
increases in fat free mass were due to muscle hypertrophy (323). Charette et al (43)
showed that older women are also able to experience strength training-related
hypertrophy. In this study, females (average age 69.9 yrs) completed 12 weeks of
strength training that resulted in a significant increase in type II muscle fiber area. This
increase in area was accompanied by significant increases in strength for each exercise
included in the strength training protocol (42). Frontera et al (92) also found that
increased muscle strength was related to muscle hypertrophy. However, in their subjects
both type I and type II muscle fibers underwent similar amounts (33.5% and 27.6%
respectively) of training induced hypertrophy (91).
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Despite many studies showing strength training is an effective intervention for
improving muscle mass and strength in older adults, questions remain about the optimal
training protocols for such interventions. For example, uncertainty still remains about the
appropriate number of sets and repetitions, and resistance to prescribe to maximize these
gains in an older population. A study by Galvão and Taaffe (95) compared the
effectiveness of 1-set and 3-set strength training programs in building muscle strength in
older adults (average age 68.9 yrs). They found that both volumes of training resulted in
significant increases in strength for all seven exercises that were involved in the training
(96). These findings indicate that the typical older adult is detrained to the point that
even low volume strength training, represented by the 1-set program, is effective in
increasing muscle strength. Vincent et al (334) studied the effects of 6 months of high-
intensity (80% of 1RM) and low-intensity (50% of 1RM) strength training of older adults
(60-83 yrs). They found that both groups significantly increased their 1RM strength for
all of the exercises involved, with no significant difference between the groups. Both
intensity levels also resulted in significant and similar increases in muscle endurance
(333). A study by Kalapotharakos et al (136) also investigated the effects of intensity on
the effectiveness of strength training protocols in older adults. They found that both
moderate and high resistance strength training led to significant increases in muscle
strength, but that the high resistance protocol resulted in increases that were significantly
greater than the moderate protocol (135). These findings are similar to those made by
Vincent et al (332) in that both studies concluded that any strength training, regardless of
intensity, is effective in increasing muscle strength in older adults. However, unlike
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Vincent et al, Kalapotharakos et al found that higher intensity training is more effective
than less challenging protocols.
Treatment for Sarcopenia and loss of function: Resistance exercise has been
shown to be effective in maintaining physical function that is usually lost as part of aging,
particularly in those afflicted with sarcopenia. Galvão and Taaffe showed that 20 weeks
of a single set strength training protocol could cause significant improvement in many
common functional tasks including chair rise, 6-m backwards walk, the 400-m walk, and
stair climb tests. This study also showed that a 3-set protocol improves performance in 6-
m walk time and floor rise to standing tests in addition to all of the functional tests which
improved with single set strength training (97). Vincent et al (331) found that strength
training, regardless of intensity, improves stair climbing performance. Furthermore, they
found significant inverse correlations between stair climbing time and leg press, leg curl,
and leg extension 1RM strength values (-0.73, -0.67, and -0.78 respectively) (330).
Similarly, Kalapotharakos et al (134) found that, when compared to control subjects,
those who underwent strength training improved functional performance regardless of
intensity. The functional tests in this study included 6-m walk time, chair rise, stair climb
and sit and reach (133). A study by Fiatarone et al (61) showed that strength training can
be effective in improving functional capacity in frail individuals at an extremely
advanced age. This study investigated the effects of strength training on people living in
nursing homes (average age 90 yrs). The 8 week, high intensity strength training resulted
in significant increases in 1RM strength as well as increased total midthigh muscle area
(9%), quadriceps area (10.9%) and hamstring and adductor area (8.4%). These
physiological increases translated into functional improvements, as walking time
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increased, some subjects needing walking aids (canes or walkers) at baseline no longer
required these devices, and some subjects who could not stand from a chair without the
use of arms at baseline became able to complete this task (60). Another study by
Fiatarone et al (65) in a similar subject group also showed that strength training can
increase muscle strength and cross-sectional area which in turn improves gait speed and
stair climbing ability. This study also found that the strength training intervention
increased spontaneous physical activity (66). Lord et al (162) investigated the effects of
exercise training on the incidence of falls in older women (average age 71.6 yrs). They
found that exercise greatly decreased the frequency of falls and those who attended more
than 75% of the exercise sessions suffered fewer falls than less dedicated exercisers and
controls. Furthermore, half as many high adherers (6.3%) experienced multiple falls
when compared to low adherers (14.8%) and controls (12.8%) (163).
Variability in Results: Despite the very strong evidence for the effectiveness of
strength training for improving muscle mass and strength both in general and in the
elderly, there is evidence for a high degree of inter-individual variability in the results of
strength training, even in people who are performing the same exercise protocol. In a
study by Fiatarone et al (59), 8 weeks of strength training in elderly people resulted in
strength gains ranging from 61% to 374%. A study by Hubal et al (123) displayed the
wide variation in muscle growth that occurs as a result of strength training. In this study,
subjects experienced muscle cross-sectional area changes ranging from -2% to 59%. The
training in this study also resulted in extremely variable strength changes. Specifically
1RM changes ranged from 0 to 250% and maximum voluntary contraction varied from -
32% to 149% (121). Studies from our laboratory have shown variation in strength
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increases ranging from <5 to >100% and muscle volume from 0 to >25% after resistance
training (129, 131, 155). One potential explanation for this variation that is present in
every study, no matter how well controlled, is genetic variation.
Muscle Heritability:
Heritability of Strength: Performance-related muscle phenotypes, including
skeletal muscle strength and mass, have been shown through twin and family studies to
be heritable. One such study by Thomis et al (296) showed high levels of heritability for
various types of muscle strength, concluding that genetic factors are responsible for up to
77% of pretraining 1RM strength, 69% of isometric strength and 65-77% of eccentric
strength in the elbow flexors(295). Another study by Thomis et al (298) concluded that
arm muscle strength has a 30-80% genetic contribution depending on the angle, type and
velocity of the contraction being performed. Furthermore, the genetic contribution for a
dynamic 1RM test was concluded to be 80% (297). In a study of 10 year old twins, Maes
et al (169) found that 72% of static arm strength was under genetic influence. A study of
sibling pairs by Zhai et al (374) found that leg muscle strength ranged from 42-59%
heritable. A study by Reed et al (242) found that grip strength also has a genetic aspect.
In their study of older adults, Reed et al found that grip strength is up to 65% heritable
when adjusting for age and various body size variables (241). A study by Arden and
Spector (8) found what they considered to be a moderate genetic component involved
with knee extensor strength and a small genetic component for grip strength in adult
twins who were in their late 50s. Specifically, they found knee extensor strength to be
46% heritable and grip strength to be 30% heritable (7). Furthermore, the influence of
genetics on these muscle phenotypes remains significant even at an advanced age. A
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study by Tiainen et al (315) investigated the heritability of muscle strength in older twins
who were an average of 68 years old. They concluded that there is a genetic component
that accounts for 14% of handgrip strength and 31% of knee extensor strength (315).
Heritability of Muscle Mass: Skeletal muscle mass has also been shown to be a
highly heritable phenotype. According to Bouchard et al (26) biological inheritance
accounts for 25-30% of the variance of fat-free mass. A later study by Arden and Spector
(6) found that genetic factors are responsible for approximately half of the total variance
of lean body mass. Specifically, they found that lean body mass was between 52 and
56% heritable depending on the covariates included in the analysis (11). A study by Loos
et al (160) concluded that up to 87-95% of the variance for muscle circumferences in the
arms and legs was due to additive genetic factors. A study by Sanchez-Andres and Mesa
(262) investigated various measures of body composition. They found that upper arm
circumference was up to 68% heritable, thigh circumference was 58% heritable and calf
circumference was 67% heritable. Furthermore, they found arm muscle area to be up to
58% heritable (264). Thomis et al (291) found that 85% of pretraining muscle cross-
sectional area can be attributed to genetic factors. A second study by Thomis et al (302)
found that arm cross-sectional area has a heritability greater than 85%.
Heritability of Strength Training Adaptation: There is also limited evidence of a
moderate interaction between genetic factors and strength training stimulus that appears
to explain some of the variation in muscle adaptation that occurs as a result of strength
training. Monozygotic twins, involved in a study by Thomis et al (290), had a correlation
of 0.46 for 1RM response to training. There was also a correlation of 0.30 in isometric
strength increases with training. Thomis et al concluded that these correlations meant
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that training-specific genetic factors accounted for 20% of the variance found in post-
training measures of 1RM and isometric strength (289). A study of the heritability of
muscle enzyme adaptation to strength training by Thibault et al (288) found that the
adaptation of some enzymes to strength training was highly variable. The authors
concluded that this variability was most likely due to genetics (288).
In summary, there is strong evidence supporting a significant genetic influence
over skeletal muscle strength and mass. There is also evidence showing an interaction
between genetic factors and strength training that affects muscle adaptation to strength
training. An important next step is to investigate specific genetic influences through the
examination of specific candidate genes that may underlie this genetic influence.
However, according to the gene map for performance and fitness phenotypes (227), very
few studies have investigated the effect that specific candidate genes have over strength
training response. Those studies that did investigate the genetic component of strength
training adaptation have successfully found genes that are partially responsible for the
accumulation of strength (44, 140). However, strength is a complex phenotype and more
candidate genes are likely to exist. Therefore, further investigation remains necessary.
Angiotensin Converting Enzyme (ACE):
One potential candidate gene is the angiotensin converting enzyme. This enzyme
is involved in the renin-angiotensin system (RAS). This system is best known for its role
in the maintenance of cardiovascular homeostasis and blood pressure regulation.
However, research also indicates that RAS, and specifically ACE, may be involved with
cell growth and muscle hypertrophy. This indicates a potential role of ACE activity, as
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dictated by ACE genotype, in skeletal muscle mass and muscle strength. ACE may also
be responsible for some of the genetic variation involved with strength training
adaptation.
Renin-Angiotensin System: The angiotensin converting enzyme plays a major role
in maintaining cardiovascular homeostasis due to its contribution to blood pressure
regulation. ACE is an important participant in both increasing vasoconstriction and
decreasing vasodilatation. As part of the RAS, ACE is responsible for converting
angiotensin I to angiotensin II: a potent vasoconstrictor. ACE is also involved in
breaking down bradykinin, a powerful vasodilator, into inactive fragments. This means
that ACE is involved in simultaneously stimulating vasoconstriction and inhibiting
vasodilatation which results in increased vascular resistance and a rise in blood pressure.
Brown et al (34) concluded that there is an inverse relationship between the half life of
bradykinin and both serum ACE activity and angiotensin II production. Therefore,
higher levels of ACE cause increases in blood pressure. While the renin-angiotensin
system is considered to be a critical component to central cardiovascular regulation,
many tissues within the human body also have a localized renin-angiotensin system
including the heart, kidneys, and lungs (56), as well as skeletal muscle (245). These
tissues contain killikrein, and therefore are able to locally produce kinins such as ACE,
which means that they are able to down regulate the activity of bradykinin (55).
Skeletal Muscle Hypertrophy: The local renin-angiotensin system in skeletal
muscle is a hormonal pathway through which muscle cell growth and hypertrophy may
be activated. Berk et al (21) and Geisterfer et al (100) have shown that adding
angiotensin II to cultured smooth muscle cells causes increases in protein synthesis and
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cell hypertrophy. Angiotensin II is also a mediator of smooth muscle cell proliferation
after vascular injury (224). Furthermore, the extent of angiotensin II stimulating smooth
muscle cell proliferation is greater in hypertensive rats when compared to normotensive
rats (207). This conclusion points to a synergism between mechanical loading and the
effects of angiotensin II on smooth muscle cells.
Similarly, angiotensin II is involved with overload-induced hypertrophy of
cardiac muscle cells (256). Much like smooth muscle, cardiac myocytes are affected
synergistically by angiotensin II and muscle overload (258). Angiotensin II also has a
proliferative effect on cardiac fibroblasts in the overloaded heart much like the effect it
has in smooth muscle (185). According to Gray et al (111), angiotensin II-induced
cardiac muscle cell proliferation contributes to cardiac myocyte hypertrophy via
paracrine growth factor secretion. According to Quinn et al (225) skeletal muscle
fibroblasts mediate skeletal myoblast proliferation through the same method, paracrine
growth factor secretion, which may lend support to the local RAS having relevance in
skeletal muscle.
A study by Silva et al (275) found that ACE influenced cardiac muscle mass only
in the presence of pressure related overload. Specifically, they found that increasing
ACE levels increased cardiac hypertrophy in response to pressure overload. However,
baseline heart mass was similar in all of the mice, regardless of ACE levels. This
suggests that it is the interaction of ACE and muscular overload that causes the change in
hypertrophy (274). These findings were similar to those of Tian et al (318). This
investigation also found no influence of ACE on initial cardiac mass. However, when the
heart experienced pressure overload, there was an influence of ACE levels (317). A
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study by Baker et al (14) found that ACE inhibitors were effective in completely
preventing overload-induced cardiac hypertrophy in rats. This suggests that ACE activity
is not only important, but possibly required for cardiac hypertrophy to occur as a result of
overload (13).
These studies led Gordon et al (105) to investigate the effects of angiotensin II
and ACE activity on overload-induced hypertrophy in skeletal muscle. In this study,
Gordon et al overloaded the plantaris and soleus muscles in the hindlimbs of rats for 28
days. Some of the rats were given ACE inhibitors and others were given saline. It was
concluded that the ACE inhibitors significantly reduced the hypertrophy in both muscles,
by 57% and 96% respectively (104). This study supported the hypothesis that
angiotensin II is important in promoting overload-induced muscle hypertrophy. A similar
study by Westerkamp and Gordon (340) confirmed these findings. That study concluded
that ACE inhibition, and thus decreased levels of angiotensin II, significantly reduced the
increases in muscle wet weights seen with muscle overload. Specifically, the wet
weights of the soleus and plantaris muscles were attenuated by 29 and 39% respectively.
In the untreated rats, the overload procedure caused increases in muscle protein content
and fiber cross-sectional area in the plantaris muscle. However, ACE inhibition also
attenuated these variables by 30 and 59% respectively (339).
A study by McBride (180) investigated the effects of blocking angiotensin type 1
(AT1) receptors on eccentric-training induced skeletal muscle hypertrophy and strength
gains. AT1 receptors are the cites where angiotensin II affects muscle cells. This study
concluded that the response of skeletal muscle to eccentric loading was significantly
attenuated when AT1 receptors were blocked. Those rats who had their receptors blocked
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were unable to experience muscle hypertrophy and increases in muscle contraction force
(179). This finding supports the conclusions drawn by Gordon et al (110) in that
decreasing angiotensin II levels significantly decreased overload-induced skeletal muscle
hypertrophy.
Conflicting Arguments: There are conflicting arguments from researchers who
have found that lower levels of ACE activity, achieved through external ACE inhibition,
actually decrease the muscle atrophy and loss of strength and function that characterizes
some disease states. A study by Onder et al (206) investigated the effects of ACE
inhibitors, as a treatment for hypertension or congestive heart failure, on isometric muscle
strength and walking speed over a three year period. They found that those women who
took ACE inhibitors had significantly less strength deterioration than those who were on
other hypertension medications or no medications at all. Similarly, they found that those
subjects who were taking ACE inhibitors better maintained their normal gait speed than
the other groups. Finally, these results were unchanged after adjustment for
cardiovascular events (205). This finding suggests that the ACE inhibitors were the
primary mediator of strength maintenance in this group of subjects. However, the
findings of this study were later challenged in a commentary by Dhatariya (50). This
commentary pointed out that Onder et al (204) failed to present the activity level of the
subjects in their various medication groups. It is possible that those who were in the
ACE inhibition group had increases in exercise tolerance, and therefore increased activity
levels. This would point to the increased activity rather than ACE inhibition as the
mechanism of muscle sparing.
53
A study by Brink et al (30) investigated the effects of angiotensin II infusions on
skeletal muscle in rats. This study found that both wet and dry muscle weights were
smaller in the angiotensin II infused rats when compared to similarly fed controls. They
concluded that the bulk of the difference was caused by impairment of the accumulation
of muscle proteins. This was decided when considering the maintenance of the fat pad
mass in the angiotensin II infused rats (29). The authors further concluded that muscle
protein synthesis was not negatively affected by the increased angiotensin II, but rather
the infusion increased the rate of protein degradation in the muscles. Finally, the authors
found that the angiotensin II infused rats had IGF-1 levels that were decreased by 33%
after 3 days and 26% after 7 days. However, when rats were infused with IGF-1 along
with the angiotensin II, they were still unable to maintain muscle mass (32). This led the
investigators to conclude that the angiotensin II may have triggered a defect in the
insulin-like growth factor-I (IGF-1) autocrine system, which represents a potential
mechanism for the increased muscle protein breakdown. It is also possible that the
angiotensin II stimulated increase in muscle degradation was caused by the stimulation of
ubiquitin-proteasome-mediated protein degradation pathway (27). Sanders et al (267)
also concluded that the ubiquitin-proteasome proteolytic pathway was the mechanism
through which angiotensin II causes muscle atrophy. This study of cancer related
cachexia found that angiotensin II up regulated this pathway resulting in increased
protein breakdown. The investigation also found that infusion of IGF-I attenuated the
increased protein degradation induced by angiotensin II. These results confirm Brink et
al’s (28) finding that IGF-I may down regulate the ubiquitin-proteasome proteolytic
pathway. Sanders et al (266) also found that muscle atrophy was attenuated with ACE
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inhibitors. This led the authors to conclude that protein catabolism caused by angiotensin
II was mediated by angiotensin I (265). Finally, a study by Song et al (279) demonstrated
that actin cleavage due to increased caspase-3 activation in skeletal muscle is the
mechanism for angiotensin II-related atrophy. The authors concluded that angiotensin II
induced muscle wasting by reducing the action of IGF-I, which in turn stimulated that
ubiquitin-proteasome proteolytic pathway. The stimulation of this pathway activated
caspase-3 which is responsible for actin cleavage (278).
In summary, angiotensin II seems to be involved with overload-related muscle
hypertrophy. It has been established that those with high levels of angiotensin II are
more likely to undergo pressure-induced cardiac hypertrophy (12, 191, 200, 259, 277,
316). Also, skeletal muscle hypertrophy has been shown in animal models to be
correlated with angiotensin II in the presence of overload (103, 338). Furthermore,
investigators have found that angiotensin II mediated skeletal muscle hypertrophy
specifically through the AT1 receptors (184). The studies that found low levels of
angiotensin II to be more effective at sparing muscle mass were frequently in diseased
states. Furthermore, they did not investigate the interaction between angiotensin II levels
and muscle overload (i.e., physical activity). This may account for the conflicted
findings.
ACE Polymorphism: The ACE gene is located on chromosome 17. Within this
gene, a 287 base pair insertion/deletion (I/D) polymorphism occurs in the 16th intron
(251). In Caucasians, the allele frequency for this insertion/deletion polymorphism is
approximately 25%, 50%, and 25% for II, ID, and DD genotypes respectively. However,
there is some evidence of a different distribution in other racial groups. In a study by
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Barley et al (19), Caucasians had a breakdown of 22%, 52% and 26% for II, ID, and DD
genotypes respectively, or a 48% I allele frequency and a 52% D allele frequency for the
entire white portion of the cohort. However, the Afro-Caribbean group demonstrated
16% II, 44% ID, and 40% DD, or a 38% I allele frequency and a 62% D allele frequency
(18). An earlier study by Barley et al (16) found similar differences between racial
groups. Specifically, this study found the distribution among Caucasians to be 24.7% II,
48.4% ID, and 26.9% DD, and Black Nigerians to be 16.2% II, 48.8% ID, and 35% DD.
This study also included Somoans (distribution: 82.8% II, 15.5% ID, and 1.7% DD) and
Yanomami Indians (distribution: 71.4% II, 26.5% ID, and 2.0% DD) (15). A third study,
once again showed variability in ACE genotype with Caucasians having 31% II, 40% ID
and 29% DD, while African Americans were 11% II, 60% ID, and 29% DD. Specifically
for the frequency of the deletion allele, the breakdown between the groups was 59% for
African Americans and 49% for Caucasians (171).
Given the evidence that ACE is important for muscle growth during overload,
several studies have examined whether the ACE I/D polymorphism is an important
moderator of cardiac muscle hypertrophy that is caused by overload. One study by
Montgomery et al (192) found that the response of cardiac mass to exercise training was
associated with ACE genotype. The training resulted in left ventricular mass increasing
2.0, 38.5 and 42.3 g in subjects with the II, ID and DD genotypes respectively (189).
These findings were supported in a study of army recruits by Myerson et al (199). This
study found no genetic effect on left ventricular mass at baseline. However, after
training, there was a highly significant difference between genotype groups.
Furthermore, the left ventricular growth was in excess of increases in lean body mass in
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DD homozygotes but when accounting for lean body mass, left ventricular hypertrophy
in II homozygotes became insignificant (198).
ACE Levels: ACE genotype is a strong marker of angiotensin-converting enzyme
activity in the body. ACE levels are very stable within people, however plasma levels
can vary up to 5.7 times among individuals (3). This association was shown in a study by
Cambien et al (39) who showed a familial similarity in plasma ACE levels that is likely
due to genetic factors. The authors concluded that the associated ACE levels were due to
genetic factors rather than shared environmental influences because the association was
limited to parent/offspring relationships and was not present between spouses (38). A
study by Alhenc-Gelas et al (2) took the opposite approach to explaining ACE levels:
testing potential environmental and hormonal factors. This study failed to identify any
environmental or hormonal factors that had a significant relationship with plasma ACE
levels (1). This study reinforces the conclusion that ACE levels are largely under genetic
control rather than being dictated by environmental or hormonal variables. Another
family study by Tiret et al (320) found that adults who were ID heterozygotes had higher
ACE activity than those who were II homozygotes. Similarly, those who were DD
homozygotes had higher levels of ACE activity than the ID heterozygotes. Furthermore,
these relationships were maintained when investigating the association between ACE
genotype and angiotensin-converting enzyme activity in the offspring of the adult
subjects (319). A study by Rigat et al (250) was able to quantify the effect of ACE
genotype on serum ACE levels to be 47%. Once again, the subjects in this study who
were carriers of the deletion allele had higher ACE levels than those who were II
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homozygotes (249). Finally, a study by Williams et al (351) concluded that circulating
ACE activity was significantly associated with ACE genotype. Specifically, the DD
homozygotes had the highest levels of ACE activity and II homozygotes had the lowest
levels of ACE activity (350). How the I/D polymorphism, located in an intron,
functionally influences ACE enzyme levels is unclear. The polymorphism may affect a
regulatory element in the gene, affecting either transcription or mRNA degradation, or
may simply act as a marker for a functional polymorphism in another region of the gene.
Despite the exact mechanism remaining a mystery, most of the studies performed have
indicated that candidate polymorphisms located in more active regions of the gene are in
tight linkage disequilibrium with the I/D polymorphism. Therefore, regardless of the
mechanism through which the I/D polymorphism affects enzyme levels, the evidence
favors the hypothesis that the I/D polymorphism serves as a marker of ACE genotype
involvement in many pathological conditions (271).
ACE Genotype & Cardiovascular Phenotypes: In addition to the strong
correlation between ACE genotype and ACE enzyme levels, ACE genotype has also been
shown to be correlated with multiple cardiovascular phenotypes. Murphey et al (194)
showed a significant correlation between ACE genotype and bradykinin degradation.
This study concluded that DD homozygotes had the greatest rate of bradykinin
metabolism and that ACE II homozygotes had the least (195). Studies have also shown
that inhibition of ACE is an appropriate method of controlling blood pressure. Fagard et
al (58) showed that inhibiting the conversion of angiotensin I to angiotensin II, is
effective at decreasing blood pressure during physical activity. The pharmacological use
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of ACE inhibitors essentially simulates a person having the II genotype. Therefore, those
who are II homozygotes may have a less drastic blood pressure effect to physical activity.
ACE genotype has also been linked to cardiovascular disease and incidence of
myocardial infarction. Cambien et al (40) observed an increased prevalence of DD
homozygotes in patients with a myocardial infarction on their medical history. Another
paper by Cambien et al (36) also concluded that men with the DD genotype were more
likely to experience myocardial infarction. This study found that being a DD
homozygote for the ACE gene is an independent risk factor for myocardial infarction.
This conclusion was made because ACE DD genotype was highly correlated with
myocardial infarction in a subpopulation who were otherwise considered low risk (37).
Mattu et al (175) found an increased likelihood of coronary artery disease in men who
were DD homozygotes for the ACE gene. This increase in frequency was maintained
regardless of these subjects being low risk for other known risk factors for coronary
artery disease (174). Raynolds et al (238) found a higher frequency of the DD genotype
in
people in the end stages of ischemic cardiomyopathy than in controls. Finally, Evans et
al (57) found a significant overrepresentation of DD homozygotes among 213 cases of
fatal myocardial infarctions.
These studies all point to the D allele as being correlated with increased risk for
various cardiovascular maladies. However, there are also studies that refute these
conclusions. Bohn et al (25) investigated the allele frequencies of a group of myocardial
infarction survivors. The investigators found that among the 234 survivors there was a
lower frequency of DD genotype (24). This conclusion was supported by other studies
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by Miettinen et al (188) and Samani et al (261). A large prospective study by
Lindpaintner et al (159) also concluded that ACE genotype is not associated with risk of
myocardial infarction. This study also found that that ACE genotype is not useful in
predicting risk of ischemic heart disease (158). Studies have also found there to be no
association between ACE genotype and coronary artery disease. Friedl et al (86) showed
that there was no correlation between ACE genotype and patience with confirmed
coronary artery disease. Katsuya et al (138) found there to be no elevation in risk for
coronary artery disease in carriers of the DD genotype. Finally a study by Winkelmann
et al (366) found that ACE genotype was not useful as a predictor of either coronary
artery disease or myocardial infarction. This conclusion was drawn because the
investigators found no evidence that the DD genotype increases the risk of either disease
(365).
If the ACE I/D polymorphism is in fact related to cardiac diseases, with carriers
of the DD genotype being at increased risk, then this suggests that the insertion allele
may be beneficial due to its lower levels of ACE activity. These beneficial effects of the
I allele on the cardiovascular system led investigators to hypothesize that those with the I
allele may be at an advantage when performing endurance activities.
ACE Genotype & Endurance Performance: The importance of ACE genotype to
cardiovascular regulation led to the first studies of ACE genotype in the context of
exercise, which were performed with endurance athletes. Many of these investigations
concluded that the ACE I/D polymorphism is related to performance in aerobic
endeavors. A study by Gayagay et al (99) examined the association between ACE
genotype and endurance performance in a group of Olympic level Australian rowers.
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This study concluded that these athletes had a significantly higher number of I alleles and
II genotypes than D alleles or DD genotypes (98). These findings were similar to those
of a study of the ACE genotype by Alvarez et al (5). This study investigated the
association between ACE genotype and endurance performance in elite athletes who
competed in cycling, long-distance running and handball. They found an excess in the
II/ID genotypes among the athletes when compared to a group of healthy controls.
Additionally, among the elite cyclists, those who were judged to be the most
accomplished were almost entirely II homozygotes or ID heterozygotes. In fact, this
group of the most elite cyclists only included one athlete who was a DD homozygote (4).
In 2001, this association was further studied, this time in high altitude mountain climbers.
This study, performed by Woods et al (370), also found an excess of the II genotype in
climbers compared to controls. Finally, these conclusions were further mirrored by a
2004 study by Tsianos et al (328) that studied elite long-distance swimmers. This study
found that the I allele was much more frequent in those athletes who competed over long
distances when compared to swimmers who competed over shorter distances.
Specifically, Tsianos et al found that the I allele frequencies were 0.59 for long-distance
swimmers as opposed to only 0.29 for those who competed in shorter events. In this
cohort, only 1 of the 15 swimmers in the long-distance group was of DD genotype (327).
ACE Genotype & Sprint Performance: Research on the ACE gene and its
association with performance led to the finding of an association of the D allele with
improved performance in power-related sports. Myerson et al (197) used a cohort of
runners to study the correlation between event distance and ACE genotype. There were
linear trends of I allele frequency increasing with distance and D allele frequency
61
increasing with decreased distance (196). There have also been two studies that have
found similar results in swimmers. The first, by Woods et al (368), found that there was
a significantly higher frequency of the D allele in the elite swimmers who competed in
events of less than 400 meters. However, this association only occurred when
investigating a cohort of truly elite swimmers. When this cohort was combined with
another group of competitive, but not elite, swimmers, the association failed to be
significant (367). The second study that investigated a cohort of swimmers was
performed by Tsianos et al (326). This study defined short-distance swimmers as those
competing in races that lasted 5 or 10 kilometers. In this cohort only one of the
individuals out of the 19 in the short-distance group had the II genotype (329). Finally, a
study by Nazarov et al (202) investigated the ACE genotype in groups of swimmers,
track and field athletes, skiers and triathletes. Once again, ACE genotype was associated
with event duration, with the athletes competing in shorter events having an excess of the
D allele. This association was observed in both the swimmers and the track and field
athletes; however, there was no association in the skiers or triathletes (201).
VO2Max: The high level of endurance performance that is correlated with the I
allele may not be the result of an advantage in aerobic capacity. One paper that did show
a correlation between ACE genotype and VO2max was by Hagberg et al (113). This study
found that, after accounting for physical activity level, VO2max was correlated with ACE
genotype, with II homozygotes testing the highest and DD homozygotes testing the
lowest. Specifically, it was concluded that ACE genotype accounted for 12% of the
inter-individual variation in VO2max (112). Conversely, other studies have shown that
there is no association. A study by Day et al (48) investigated the association between
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ACE genotype, circulating ACE activity, and VO2max in sedentary females. This study
showed no correlation between either ACE genotype or ACE activity and VO2max when
exercising on a cycle ergometer (47). A study by Rankinen et al (229) investigated the
effects of ACE genotype on various aspects of aerobic fitness, including VO2max. This
study found that there was no correlation between ACE genotype and VO2max at baseline.
It also found that the DD homozygotes, rather than the II homozygotes as expected,
underwent greater improvements in VO2max with aerobic training. However, this finding
was only true in Caucasian offspring and all other groups showed no correlation with
training effect. Thus, it was concluded that ACE genotype was not a major contributor of
VO2max at either baseline or as a result of training (228). Another study by Rankinen et al
(231) further investigated the association between ACE genotype and VO2max, this time in
aerobically trained athletes. Once again they found no correlation between the II
genotype, or the I allele, and high levels of cardiorespiratory fitness as measured by
VO2max (230). Finally, Woods et al (372) found that there was no significant difference in
baseline VO2max between II and DD homozygotes. Similarly, they showed no
gene*training interaction effect on VO2max in these same groups (371).
Muscle Efficiency: If ACE genotype doesn’t affect endurance performance
through improved aerobic capacity, then the mechanism of advantage may be involved
with muscular efficiency. A study by Williams et al (363) investigated the association
between ACE genotype and the mechanical efficiency (energy used per unit power
output) of skeletal muscle. They found that the insertion allele enhances mechanical
efficiency in trained muscle. The authors suggested two potential mechanisms from this
improved efficiency, both directly effecting skeletal muscle tissue. The first possible
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mechanism was the increased number of slow-twitch muscle fibers (362). Muscle fibers
of this type are known to be more efficient in slow contractions (45). The second
mechanism suggested by the authors is that II homozygotes may have higher levels of
nitric oxide concentrations, which would in turn raise mitochondrial efficiency and thus
contractile function in skeletal muscle (361). A study by Zhang et al (377) seemed to
support the first potential mechanism. This study investigated the possible association
between ACE genotype and percentage of slow-twitch, type I muscle fibers. They
concluded that there was a positive trend connecting ACE genotype with number of type
I fibers. Specifically, ACE II homozygotes had the highest number of type I slow-twitch
fibers, followed by ID heterozygotes and DD homozygotes. Furthermore, the ID
heterozygotes had significantly more type I fibers than DD homozygotes (376). These
studies suggest that the effect of ACE genotype on endurance performance may exist at
the muscular level rather than at the level of the cardiovascular system. This sediment is
shared by Jones et al (132) who concluded in their review of ACE genotype and human
performance that the enhanced endurance that is associated with the I allele stems from a
local increase in muscle efficiency rather than a central cardiorespiratory effect.
ACE Genotype & Muscle Adaptation to Strength Training: The association
between sprint type events and the D allele gave forth to investigations into a potential
connection between ACE genotype and strength training-related muscle phenotypes. The
idea of studying ACE genotype in conjunction with strength training was also indirectly
supported by studies showing its relationship with muscle hypertrophy, discussed above.
The first such investigation came in 2000 when Folland et al (83) studied the effect of
ACE genotype on the skeletal muscle response to resistance training. In this study, the
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subjects were all 18-30 year old males and the training stimulus was single-leg, knee
extension strength training. In this protocol, one leg was trained entirely isometrically,
while the opposing leg was trained in a more typical, dynamic manner. This study
showed a gene*environment interaction between ACE and resistance training. More
specifically, Folland et al (71) concluded that there was no association between ACE and
strength in the untrained state, a small association with the dynamic training protocol, and
a significant association with isometric strength training. Finally, it was concluded that
those subjects with the D allele of the ACE gene had greater increases in all of the
strength measurements taken compared to those who were homogeneous for the I allele
(70). This study showed not only that there is a gene-environment interaction involving
ACE genotype, but also that the magnitude of that interaction may be based on the mode
of the training stimulus.
A second study that used a leg training protocol to investigate ACE was done by
Williams et al (349). This group aimed to investigate the relationship between ACE
activity and strength response to training. The subject pool in this cohort was made up of
white males with the average age of 22 years. They performed 4 sets of 10 repetitions at
their 10 rep max for 24 training sessions (348). This study also found an association
between ACE genotype and muscle strength, however the association was different from
that reported by Folland et al. Williams et al stated that pretraining strength was in fact
correlated with circulating ACE activity, which in turn was correlated with ACE
genotype, with those carrying at least one D allele having elevated ACE activity. More
specifically, those subjects with higher circulating ACE levels also had higher isometric
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strength in the untrained state. Conversely, the training related changes in muscle
strength were found to be independent of ACE genotype (347).
There have also been two studies that have used upper arm resistance training
protocols to study the association of ACE genotype with strength phenotypes. One
example of these studies is by Pescatello et al (220). They used a progressive, unilateral
training program consisting of 3 sets of 12 repetitions of five biceps and triceps exercises.
This protocol was used in a cohort of 367 men and 264 women with a mean age of 24.2
years, 79.5% of whom were Caucasian, out of the FAMuSS study (221). The findings in
this study were counter to those in the previous investigations in that those subjects with
the I allele had greater gains in maximum voluntary contraction in both the trained and
untrained arms; however, those with the D allele had greater increases in 1RM and
muscle mass in the untrained arm. Finally, ACE genotype was not related to baseline
measures of strength or size (218). The second study that used an upper arm training
protocol was published in 2004 by Thomis et al (311), and investigated the effects of 10
weeks of biceps training on male twins. They concluded that ACE genotype had no
effect on 1RM strength or torque (310).
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No No No No
No: no significant association of ACE genotype with phenotype. Yes: significant
association of ACE genotype with phenotype. “-“: not studied.
In summary, the findings that ACE genotype is correlated with sprint/power
performance and that ACE genotype may affect skeletal muscle in the periphery through
its relationship with muscle efficiency promote the possibility of the gene’s association
with strength training. Furthermore, the role of angiotensin II in muscle hypertrophy
provides a possible mechanism, which increases the likelihood of the ACE gene’s
involvement in muscle strength and mass. As shown in Table D1, only four studies to
date have investigated this potential relationship, with inconsistent results. Specifically,
two studies have found a gene*environment interaction, albeit conflicting interactions
(67, 219), one study found a correlation between ACE genotype and baseline strength
(346), and one study found no relationship at all (309). However, there are some
important inconsistencies and limitations in these studies. For the most part, these studies
investigated small sample sizes. Three of the studies had samples under 100 people (81,
33, and 50 respectively) (69, 308, 345). The two studies that investigated leg training
protocols (Folland et al and Williams et al) also had inconsistency between their testing
protocols and their training protocols (68, 359). Both of these studies involved strength
interventions using dynamic training. However, Williams et al used isometric and
isokinetic tests of strength. Similarly, Folland et al used only isometric tests to evaluate
strength after subjects performed dynamic strength training with one leg and isometric
training with the other. Clearly, these testing methods ignore the principle of specificity
and may underreport strength gains.
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ACE Genotyping Methods: Genotyping of the ACE I/D polymorphism is
performed using a polymerase chain reaction (PCR)-based DNA amplification using
flanking primers. The sense primer sequence is 5'
CTGGAGACCACTCCCATCCTTTTCT 3' and the antisense primer is 5'
GATGTGGCCATCACATTCGTCAGAT 3'. The PCR product is a 190 base pair
fragment for the deletion (D) genotype and a 490 base pair fragment for the insertion (I)
genotype (248, 325). Therefore, a single band of either 190 or 490 base pairs denoted a
homozygote for either the insertion or deletion genotype, respectively, and two bands
stemming from the same sample confirmed an ID heterozygote. Genotyping is
performed by separating the PCR amplicon on a 2% agarose gel with ethidium bromide
staining with UV transillumination (325).
Summary:
Skeletal muscle is important in determining many performance and functional
capabilities. This is particularly true as people age and everyday tasks become more
difficult to complete. Older individuals who lack muscle strength are far more likely to
experience limited mobility, reduced independence and decreased quality of life. This
lack of strength among the elderly tends to be correlated with the loss of muscle mass
with age, known as sarcopenia.
Strength training interventions work to increase muscle strength and mass in both
young and old populations. In fact, many studies have concluded that strength training
interventions can have similar relative effects independent of age. Strength training
interventions are able to improve functional abilities in addition to increasing muscle
strength and mass. In older adults, strength training results in improved performance on
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functional tests including gait speed, chair rise and stair climb tests. This suggests that
strength training is an appropriate intervention in the attempt to combat the functional
losses involved with sarcopenia. However, within these training studies, investigators
have found large amounts of variability among individual subjects despite applying
consistent training stimuli. This suggests a genetic influence that is involved in muscle
strength and mass responses to training. Accordingly, family and twin studies have
shown heritability of muscle strength and mass both at baseline and after strength
training. There have also been studies that have shown a gene*training interaction that
may affect an individual’s ability to respond to strength training.
Investigation of the ACE gene’s I/D polymorphism began with researching its
involvement in the cardiovascular system and its relationship with various cardiovascular
phenotypes including blood pressure and left ventricular hypertrophy. These studies
showed that lower levels of ACE activity, associated with the I allele, promote
cardiovascular health. This conclusion led to the investigation of ACE genotype in
relation to endurance performance. These studies concluded that the I allele was
correlated with high levels of endurance performance; however, an unexpected
correlation between sprint/power performance and the D allele was also discovered. One
potential explanation for this is that carriers of the I allele may have a higher aerobic
capacity. However, VO2max does not consistently vary with ACE genotype. On the
other hand, muscle efficiency does seem to be associated with ACE genotype, suggesting
that ACE genotype may directly affect the skeletal muscles rather than having only
central effects. ACE and angiotensin II have been shown to be involved in both cardiac
and skeletal muscle hypertrophy. The peripheral effects of ACE along with the
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correlation of the D allele and sprint/power performance suggest that ACE genotype may
have an effect on strength training adaptation. Unfortunately, the studies that have
investigated this relationship have been inconsistent with their methods and results and
therefore more research is needed to fully understand this potential association.
Therefore, the purpose of the proposed study was to investigate the possible association
between ACE genotype and skeletal muscle strength and mass, and their adaptation to
strength training in older adults.




1. Alhenc-Gelas F, Richard J, Courbon D, Warnet JM and Corvol P. Distribution of
plasma angiotensin I-converting enzyme levels in healthy men: relationship to
environmental and hormonal parameters. J Lab Clin Med 117: 33-39, 1991.
2. Alhenc-Gelas F, Richard J, Courbon D, Warnet JM and Corvol P. Distribution of
plasma angiotensin I-converting enzyme levels in healthy men: relationship to
environmental and hormonal parameters. J Lab Clin Med 117: 33-39, 1991.
3. Alhenc-Gelas F, Richard J, Courbon D, Warnet JM and Corvol P. Distribution of
plasma angiotensin I-converting enzyme levels in healthy men: relationship to
environmental and hormonal parameters. J Lab Clin Med 117: 33-39, 1991.
4. Alvarez R, Terrados N, Ortolano R, Iglesias-Cubero G, Reguero JR, Batalla A,
Cortina A, Fernandez-Garcia B, Rodriguez C, Braga S, Alvarez V and Coto E.
Genetic variation in the renin-angiotensin system and athletic performance. Eur J
Appl Physiol 82: 117-120, 2000.
5. Alvarez R, Terrados N, Ortolano R, Iglesias-Cubero G, Reguero JR, Batalla A,
Cortina A, Fernandez-Garcia B, Rodriguez C, Braga S, Alvarez V and Coto E.
Genetic variation in the renin-angiotensin system and athletic performance. Eur J
Appl Physiol 82: 117-120, 2000.
72
6. Arden NK and Spector TD. Genetic influences on muscle strength, lean body
mass, and bone mineral density: a twin study. J Bone Miner Res 12: 2076-2081,
1997.
7. Arden NK and Spector TD. Genetic influences on muscle strength, lean body
mass, and bone mineral density: a twin study. J Bone Miner Res 12: 2076-2081,
1997.
8. Arden NK and Spector TD. Genetic influences on muscle strength, lean body
mass, and bone mineral density: a twin study. J Bone Miner Res 12: 2076-2081,
1997.
9. Arden NK and Spector TD. Genetic influences on muscle strength, lean body
mass, and bone mineral density: a twin study. J Bone Miner Res 12: 2076-2081,
1997.
10. Arden NK and Spector TD. Genetic influences on muscle strength, lean body
mass, and bone mineral density: a twin study. J Bone Miner Res 12: 2076-2081,
1997.
11. Arden NK and Spector TD. Genetic influences on muscle strength, lean body
mass, and bone mineral density: a twin study. J Bone Miner Res 12: 2076-2081,
1997.
73
12. Baker KM, Chernin MI, Wixson SK and Aceto JF. Renin-angiotensin system
involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 259:
H324-H332, 1990.
13. Baker KM, Chernin MI, Wixson SK and Aceto JF. Renin-angiotensin system
involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 259:
H324-H332, 1990.
14. Baker KM, Chernin MI, Wixson SK and Aceto JF. Renin-angiotensin system
involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol 259:
H324-H332, 1990.
15. Barley J, Blackwood A, Carter ND, Crews DE, Cruickshank JK, Jeffery S,
Ogunlesi AO and Sagnella GA. Angiotensin converting enzyme insertion/deletion
polymorphism: association with ethnic origin. J Hypertens 12: 955-957, 1994.
16. Barley J, Blackwood A, Carter ND, Crews DE, Cruickshank JK, Jeffery S,
Ogunlesi AO and Sagnella GA. Angiotensin converting enzyme insertion/deletion
polymorphism: association with ethnic origin. J Hypertens 12: 955-957, 1994.
17. Barley J, Blackwood A, Carter ND, Crews DE, Cruickshank JK, Jeffery S,
Ogunlesi AO and Sagnella GA. Angiotensin converting enzyme insertion/deletion
polymorphism: association with ethnic origin. J Hypertens 12: 955-957, 1994.
74
18. Barley J, Blackwood A, Miller M, Markandu ND, Carter ND, Jeffery S,
Cappuccio FP, MacGregor GA and Sagnella GA. Angiotensin converting enzyme
gene I/D polymorphism, blood pressure and the renin-angiotensin system in
Caucasian and Afro-Caribbean peoples. J Hum Hypertens 10: 31-35, 1996.
19. Barley J, Blackwood A, Miller M, Markandu ND, Carter ND, Jeffery S,
Cappuccio FP, MacGregor GA and Sagnella GA. Angiotensin converting enzyme
gene I/D polymorphism, blood pressure and the renin-angiotensin system in
Caucasian and Afro-Caribbean peoples. J Hum Hypertens 10: 31-35, 1996.
20. Barley J, Blackwood A, Miller M, Markandu ND, Carter ND, Jeffery S,
Cappuccio FP, MacGregor GA and Sagnella GA. Angiotensin converting enzyme
gene I/D polymorphism, blood pressure and the renin-angiotensin system in
Caucasian and Afro-Caribbean peoples. J Hum Hypertens 10: 31-35, 1996.
21. Berk BC, Vekshtein V, Gordon HM and Tsuda T. Angiotensin II-stimulated
protein synthesis in cultured vascular smooth muscle cells. Hypertension 13: 305-
314, 1989.
22. Berk BC, Vekshtein V, Gordon HM and Tsuda T. Angiotensin II-stimulated
protein synthesis in cultured vascular smooth muscle cells. Hypertension 13: 305-
314, 1989.
75
23. Berk BC, Vekshtein V, Gordon HM and Tsuda T. Angiotensin II-stimulated
protein synthesis in cultured vascular smooth muscle cells. Hypertension 13: 305-
314, 1989.
24. Bohn M, Berge KE, Bakken A, Erikssen J and Berg K. Insertion/deletion (I/D)
polymorphism at the locus for angiotensin I-converting enzyme and myocardial
infarction. Clin Genet 44: 292-297, 1993.
25. Bohn M, Berge KE, Bakken A, Erikssen J and Berg K. Insertion/deletion (I/D)
polymorphism at the locus for angiotensin I-converting enzyme and myocardial
infarction. Clin Genet 44: 292-297, 1993.
26. Bouchard C, Perusse L, Leblanc C, Tremblay A and Theriault G. Inheritance of
the amount and distribution of human body fat. Int J Obes 12: 205-215, 1988.
27. Brink M, Anwar A and Delafontaine P. Neurohormonal factors in the
development of catabolic/anabolic imbalance and cachexia. Int J Cardiol 85: 111-
21, discussion, 2002.
28. Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE and Delafontaine P.
Angiotensin II induces skeletal muscle wasting through enhanced protein
degradation and down-regulates autocrine insulin-like growth factor I.
Endocrinology 142: 1489-1496, 2001.
76
29. Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE and Delafontaine P.
Angiotensin II induces skeletal muscle wasting through enhanced protein
degradation and down-regulates autocrine insulin-like growth factor I.
Endocrinology 142: 1489-1496, 2001.
30. Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE and Delafontaine P.
Angiotensin II induces skeletal muscle wasting through enhanced protein
degradation and down-regulates autocrine insulin-like growth factor I.
Endocrinology 142: 1489-1496, 2001.
31. Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE and Delafontaine P.
Angiotensin II induces skeletal muscle wasting through enhanced protein
degradation and down-regulates autocrine insulin-like growth factor I.
Endocrinology 142: 1489-1496, 2001.
32. Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE and Delafontaine P.
Angiotensin II induces skeletal muscle wasting through enhanced protein
degradation and down-regulates autocrine insulin-like growth factor I.
Endocrinology 142: 1489-1496, 2001.
33. Brooks SV and Faulkner JA. Skeletal muscle weakness in old age: underlying
mechanisms. Med Sci Sports Exerc 26: 432-439, 1994.
77
34. Brown NJ, Blais C, Jr., Gandhi SK and Adam A. ACE insertion/deletion
genotype affects bradykinin metabolism. J Cardiovasc Pharmacol 32: 373-377,
1998.
35. Buikema H, Pinto YM, Rooks G, Grandjean JG, Schunkert H and van Gilst WH.
The deletion polymorphism of the angiotensin-converting enzyme gene is related
to phenotypic differences in human arteries. Eur Heart J 17: 787-794, 1996.
36. Cambien F, Costerousse O, Tiret L, Poirier O, Lecerf L, Gonzales MF, Evans A,
Arveiler D, Cambou JP, Luc G and . Plasma level and gene polymorphism of
angiotensin-converting enzyme in relation to myocardial infarction. Circulation
90: 669-676, 1994.
37. Cambien F, Costerousse O, Tiret L, Poirier O, Lecerf L, Gonzales MF, Evans A,
Arveiler D, Cambou JP, Luc G and . Plasma level and gene polymorphism of
angiotensin-converting enzyme in relation to myocardial infarction. Circulation
90: 669-676, 1994.
38. Cambien F, henc-Gelas F, Herbeth B, Andre JL, Rakotovao R, Gonzales MF,
Allegrini J and Bloch C. Familial resemblance of plasma angiotensin-converting
enzyme level: the Nancy Study. Am J Hum Genet 43: 774-780, 1988.
78
39. Cambien F, henc-Gelas F, Herbeth B, Andre JL, Rakotovao R, Gonzales MF,
Allegrini J and Bloch C. Familial resemblance of plasma angiotensin-converting
enzyme level: the Nancy Study. Am J Hum Genet 43: 774-780, 1988.
40. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard
JM, Bara L, Ricard S, Alhenc-Gelas F and Soubrier F. Deletion polymorphism in
the gene for angiotensin-converting enzyme is a potent risk factor for myocardial
infarction. Nature 359: 641-644, 1992.
41. Campbell AJ, Borrie MJ and Spears GF. Risk factors for falls in a community-
based prospective study of people 70 years and older. J Gerontol 44: M112-
M117, 1989.
42. Charette SL, McEvoy L, Pyka G, Snow-Harter C, Guido D, Wiswell RA and
Marcus R. Muscle hypertrophy response to resistance training in older women. J
Appl Physiol 70: 1912-1916, 1991.
43. Charette SL, McEvoy L, Pyka G, Snow-Harter C, Guido D, Wiswell RA and
Marcus R. Muscle hypertrophy response to resistance training in older women. J
Appl Physiol 70: 1912-1916, 1991.
44. Clarkson PM, Devaney JM, Gordish-Dressman H, Thompson PD, Hubal MJ,
Urso M, Price TB, Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello LS,
Visich PS, Zoeller RF, Seip RL and Hoffman EP. ACTN3 genotype is associated
79
with increases in muscle strength in response to resistance training in women. J
Appl Physiol 99: 154-163, 2005.
45. Coyle EF, Sidossis LS, Horowitz JF and Beltz JD. Cycling efficiency is related to
the percentage of type I muscle fibers. Med Sci Sports Exerc 24: 782-788, 1992.
46. Danser AH, Schalekamp MA, Bax WA, van den Brink AM, Saxena PR, Riegger
GA and Schunkert H. Angiotensin-converting enzyme in the human heart. Effect
of the deletion/insertion polymorphism. Circulation 92: 1387-1388, 1995.
47. Day SH, Gohlke P, Dhamrait SS and Williams AG. No correlation between
circulating ACE activity and VO2max or mechanical efficiency in women. Eur J
Appl Physiol 99: 11-18, 2007.
48. Day SH, Gohlke P, Dhamrait SS and Williams AG. No correlation between
circulating ACE activity and VO2max or mechanical efficiency in women. Eur J
Appl Physiol 99: 11-18, 2007.
49. Dhatariya K. Inhibitors of angiotensin-converting enzyme and physical function
in older women. Lancet 360: 1098-1099, 2002.
50. Dhatariya K. Inhibitors of angiotensin-converting enzyme and physical function
in older women. Lancet 360: 1098-1099, 2002.
80
51. Dons B, Bollerup K, Bonde-Petersen F and Hancke S. The effect of weight-lifting
exercise related to muscle fiber composition and muscle cross-sectional area in
humans. Eur J Appl Physiol Occup Physiol 40: 95-106, 1979.
52. Dons B, Bollerup K, Bonde-Petersen F and Hancke S. The effect of weight-lifting
exercise related to muscle fiber composition and muscle cross-sectional area in
humans. Eur J Appl Physiol Occup Physiol 40: 95-106, 1979.
53. Dons B, Bollerup K, Bonde-Petersen F and Hancke S. The effect of weight-lifting
exercise related to muscle fiber composition and muscle cross-sectional area in
humans. Eur J Appl Physiol Occup Physiol 40: 95-106, 1979.
54. Dons B, Bollerup K, Bonde-Petersen F and Hancke S. The effect of weight-lifting
exercise related to muscle fiber composition and muscle cross-sectional area in
humans. Eur J Appl Physiol Occup Physiol 40: 95-106, 1979.
55. Dragovic T, Minshall R, Jackman HL, Wang LX and Erdos EG. Kininase II-type
enzymes. Their putative role in muscle energy metabolism. Diabetes 45 Suppl 1:
S34-S37, 1996.
56. Dragovic T, Minshall R, Jackman HL, Wang LX and Erdos EG. Kininase II-type
enzymes. Their putative role in muscle energy metabolism. Diabetes 45 Suppl 1:
S34-S37, 1996.
81
57. Evans AE, Poirier O, Kee F, Lecerf L, McCrum E, Falconer T, Crane J, O'Rourke
DF and Cambien F. Polymorphisms of the angiotensin-converting-enzyme gene
in subjects who die from coronary heart disease. Q J Med 87: 211-214, 1994.
58. Fagard R, Lijnen P, Vanhees L and Amery A. Hemodynamic response to
converting enzyme inhibition at rest and exercise in humans. J Appl Physiol 53:
576-581, 1982.
59. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA and Evans WJ.
High-intensity strength training in nonagenarians. Effects on skeletal muscle.
JAMA 263: 3029-3034, 1990.
60. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA and Evans WJ.
High-intensity strength training in nonagenarians. Effects on skeletal muscle.
JAMA 263: 3029-3034, 1990.
61. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA and Evans WJ.
High-intensity strength training in nonagenarians. Effects on skeletal muscle.
JAMA 263: 3029-3034, 1990.
62. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA and Evans WJ.
High-intensity strength training in nonagenarians. Effects on skeletal muscle.
JAMA 263: 3029-3034, 1990.
82
63. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA and Evans WJ.
High-intensity strength training in nonagenarians. Effects on skeletal muscle.
JAMA 263: 3029-3034, 1990.
64. Fiatarone MA, Marks EC, Ryan ND, Meredith CN, Lipsitz LA and Evans WJ.
High-intensity strength training in nonagenarians. Effects on skeletal muscle.
JAMA 263: 3029-3034, 1990.
65. Fiatarone MA, O'Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME,
Roberts SB, Kehayias JJ, Lipsitz LA and Evans WJ. Exercise training and
nutritional supplementation for physical frailty in very elderly people. N Engl J
Med 330: 1769-1775, 1994.
66. Fiatarone MA, O'Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME,
Roberts SB, Kehayias JJ, Lipsitz LA and Evans WJ. Exercise training and
nutritional supplementation for physical frailty in very elderly people. N Engl J
Med 330: 1769-1775, 1994.
67. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
83
68. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
69. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
70. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
71. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
72. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
73. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
84
74. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
75. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
76. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
77. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
78. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
79. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
85
80. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
81. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
82. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
83. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
84. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
85. Folland J, Leach B, Little T, Hawker K, Myerson S, Montgomery H and Jones D.
Angiotensin-converting enzyme genotype affects the response of human skeletal
muscle to functional overload. Exp Physiol 85: 575-579, 2000.
86
86. Friedl W, Krempler F, Paulweber B, Pichler M and Sandhofer F. A deletion
polymorphism in the angiotensin converting enzyme gene is not associated with
coronary heart disease in an Austrian population. Atherosclerosis 112: 137-143,
1995.
87. Frontera WR, Hughes VA, Fielding RA, Fiatarone MA, Evans WJ and Roubenoff
R. Aging of skeletal muscle: a 12-yr longitudinal study. J Appl Physiol 88: 1321-
1326, 2000.
88. Frontera WR, Hughes VA, Lutz KJ and Evans WJ. A cross-sectional study of
muscle strength and mass in 45- to 78-yr-old men and women. J Appl Physiol 71:
644-650, 1991.
89. Frontera WR, Hughes VA, Lutz KJ and Evans WJ. A cross-sectional study of
muscle strength and mass in 45- to 78-yr-old men and women. J Appl Physiol 71:
644-650, 1991.
90. Frontera WR, Hughes VA, Lutz KJ and Evans WJ. A cross-sectional study of
muscle strength and mass in 45- to 78-yr-old men and women. J Appl Physiol 71:
644-650, 1991.
91. Frontera WR, Meredith CN, O'Reilly KP, Knuttgen HG and Evans WJ. Strength
conditioning in older men: skeletal muscle hypertrophy and improved function. J
Appl Physiol 64: 1038-1044, 1988.
87
92. Frontera WR, Meredith CN, O'Reilly KP, Knuttgen HG and Evans WJ. Strength
conditioning in older men: skeletal muscle hypertrophy and improved function. J
Appl Physiol 64: 1038-1044, 1988.
93. Frontera WR, Meredith CN, O'Reilly KP, Knuttgen HG and Evans WJ. Strength
conditioning in older men: skeletal muscle hypertrophy and improved function. J
Appl Physiol 64: 1038-1044, 1988.
94. Frontera WR, Meredith CN, O'Reilly KP, Knuttgen HG and Evans WJ. Strength
conditioning in older men: skeletal muscle hypertrophy and improved function. J
Appl Physiol 64: 1038-1044, 1988.
95. Galvao DA and Taaffe DR. Resistance exercise dosage in older adults: single-
versus multiset effects on physical performance and body composition. J Am
Geriatr Soc 53: 2090-2097, 2005.
96. Galvao DA and Taaffe DR. Resistance exercise dosage in older adults: single-
versus multiset effects on physical performance and body composition. J Am
Geriatr Soc 53: 2090-2097, 2005.
97. Galvao DA and Taaffe DR. Resistance exercise dosage in older adults: single-
versus multiset effects on physical performance and body composition. J Am
Geriatr Soc 53: 2090-2097, 2005.
88
98. Gayagay G, Yu B, Hambly B, Boston T, Hahn A, Celermajer DS and Trent RJ.
Elite endurance athletes and the ACE I allele--the role of genes in athletic
performance. Hum Genet 103: 48-50, 1998.
99. Gayagay G, Yu B, Hambly B, Boston T, Hahn A, Celermajer DS and Trent RJ.
Elite endurance athletes and the ACE I allele--the role of genes in athletic
performance. Hum Genet 103: 48-50, 1998.
100. Geisterfer AA, Peach MJ and Owens GK. Angiotensin II induces hypertrophy,
not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 62: 749-756,
1988.
101. Geisterfer AA, Peach MJ and Owens GK. Angiotensin II induces hypertrophy,
not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 62: 749-756,
1988.
102. Geisterfer AA, Peach MJ and Owens GK. Angiotensin II induces hypertrophy,
not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 62: 749-756,
1988.
103. Gordon SE, Davis BS, Carlson CJ and Booth FW. ANG II is required for optimal
overload-induced skeletal muscle hypertrophy. Am J Physiol Endocrinol Metab
280: E150-E159, 2001.
89
104. Gordon SE, Davis BS, Carlson CJ and Booth FW. ANG II is required for optimal
overload-induced skeletal muscle hypertrophy. Am J Physiol Endocrinol Metab
280: E150-E159, 2001.
105. Gordon SE, Davis BS, Carlson CJ and Booth FW. ANG II is required for optimal
overload-induced skeletal muscle hypertrophy. Am J Physiol Endocrinol Metab
280: E150-E159, 2001.
106. Gordon SE, Davis BS, Carlson CJ and Booth FW. ANG II is required for optimal
overload-induced skeletal muscle hypertrophy. Am J Physiol Endocrinol Metab
280: E150-E159, 2001.
107. Gordon SE, Davis BS, Carlson CJ and Booth FW. ANG II is required for optimal
overload-induced skeletal muscle hypertrophy. Am J Physiol Endocrinol Metab
280: E150-E159, 2001.
108. Gordon SE, Davis BS, Carlson CJ and Booth FW. ANG II is required for optimal
overload-induced skeletal muscle hypertrophy. Am J Physiol Endocrinol Metab
280: E150-E159, 2001.
109. Gordon SE, Davis BS, Carlson CJ and Booth FW. ANG II is required for optimal
overload-induced skeletal muscle hypertrophy. Am J Physiol Endocrinol Metab
280: E150-E159, 2001.
90
110. Gordon SE, Davis BS, Carlson CJ and Booth FW. ANG II is required for optimal
overload-induced skeletal muscle hypertrophy. Am J Physiol Endocrinol Metab
280: E150-E159, 2001.
111. Gray MO, Long CS, Kalinyak JE, Li HT and Karliner JS. Angiotensin II
stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and
endothelin-1 from fibroblasts. Cardiovasc Res 40: 352-363, 1998.
112. Hagberg JM, Ferrell RE, McCole SD, Wilund KR and Moore GE. VO2 max is
associated with ACE genotype in postmenopausal women. J Appl Physiol 85:
1842-1846, 1998.
113. Hagberg JM, Ferrell RE, McCole SD, Wilund KR and Moore GE. VO2 max is
associated with ACE genotype in postmenopausal women. J Appl Physiol 85:
1842-1846, 1998.
114. Haggmark T, Jansson E and Svane B. Cross-sectional area of the thigh muscle in
man measured by computed tomography. Scand J Clin Lab Invest 38: 355-360,
1978.
115. Haggmark T, Jansson E and Svane B. Cross-sectional area of the thigh muscle in
man measured by computed tomography. Scand J Clin Lab Invest 38: 355-360,
1978.
91
116. Haggmark T, Jansson E and Svane B. Cross-sectional area of the thigh muscle in
man measured by computed tomography. Scand J Clin Lab Invest 38: 355-360,
1978.
117. Haggmark T, Jansson E and Svane B. Cross-sectional area of the thigh muscle in
man measured by computed tomography. Scand J Clin Lab Invest 38: 355-360,
1978.
118. Hakkinen K, Kallinen M, Izquierdo M, Jokelainen K, Lassila H, Malkia E,
Kraemer WJ, Newton RU and Alen M. Changes in agonist-antagonist EMG,
muscle CSA, and force during strength training in middle-aged and older people.
J Appl Physiol 84: 1341-1349, 1998.
119. Hakkinen K, Kallinen M, Izquierdo M, Jokelainen K, Lassila H, Malkia E,
Kraemer WJ, Newton RU and Alen M. Changes in agonist-antagonist EMG,
muscle CSA, and force during strength training in middle-aged and older people.
J Appl Physiol 84: 1341-1349, 1998.
120. Heyward VH. Advanced Fitness Assessment and Exercise Prescription. Human
Kinetics, 1998.
121. Hubal MJ, Gordish-Dressman H, Thompson PD, Price TB, Hoffman EP,
Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF,
92
Seip RL and Clarkson PM. Variability in muscle size and strength gain after
unilateral resistance training. Med Sci Sports Exerc 37: 964-972, 2005.
122. Hubal MJ, Gordish-Dressman H, Thompson PD, Price TB, Hoffman EP,
Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF,
Seip RL and Clarkson PM. Variability in muscle size and strength gain after
unilateral resistance training. Med Sci Sports Exerc 37: 964-972, 2005.
123. Hubal MJ, Gordish-Dressman H, Thompson PD, Price TB, Hoffman EP,
Angelopoulos TJ, Gordon PM, Moyna NM, Pescatello LS, Visich PS, Zoeller RF,
Seip RL and Clarkson PM. Variability in muscle size and strength gain after
unilateral resistance training. Med Sci Sports Exerc 37: 964-972, 2005.
124. Hurley BF, Redmond RA, Pratley RE, Treuth MS, Rogers MA and Goldberg AP.
Effects of strength training on muscle hypertrophy and muscle cell disruption in
older men. Int J Sports Med 16: 378-384, 1995.
125. Hurley BF, Redmond RA, Pratley RE, Treuth MS, Rogers MA and Goldberg AP.
Effects of strength training on muscle hypertrophy and muscle cell disruption in
older men. Int J Sports Med 16: 378-384, 1995.
126. Hurley BF, Redmond RA, Pratley RE, Treuth MS, Rogers MA and Goldberg AP.
Effects of strength training on muscle hypertrophy and muscle cell disruption in
older men. Int J Sports Med 16: 378-384, 1995.
93
127. Hurley BF, Redmond RA, Pratley RE, Treuth MS, Rogers MA and Goldberg AP.
Effects of strength training on muscle hypertrophy and muscle cell disruption in
older men. Int J Sports Med 16: 378-384, 1995.
128. Ivey FM, Roth SM, Ferrell RE, Tracy BL, Lemmer JT, Hurlbut DE, Martel GF,
Siegel EL, Fozard JL, Jeffrey ME, Fleg JL and Hurley BF. Effects of age, gender,
and myostatin genotype on the hypertrophic response to heavy resistance strength
training. J Gerontol A Biol Sci Med Sci 55: M641-M648, 2000.
129. Ivey FM, Roth SM, Ferrell RE, Tracy BL, Lemmer JT, Hurlbut DE, Martel GF,
Siegel EL, Fozard JL, Jeffrey ME, Fleg JL and Hurley BF. Effects of age, gender,
and myostatin genotype on the hypertrophic response to heavy resistance strength
training. J Gerontol A Biol Sci Med Sci 55: M641-M648, 2000.
130. Ivey FM, Tracy BL, Lemmer JT, NessAiver M, Metter EJ, Fozard JL and Hurley
BF. Effects of strength training and detraining on muscle quality: age and gender
comparisons. J Gerontol A Biol Sci Med Sci 55: B152-B157, 2000.
131. Ivey FM, Tracy BL, Lemmer JT, NessAiver M, Metter EJ, Fozard JL and Hurley
BF. Effects of strength training and detraining on muscle quality: age and gender
comparisons. J Gerontol A Biol Sci Med Sci 55: B152-B157, 2000.
132. Jones A, Montgomery HE and Woods DR. Human performance: a role for the
ACE genotype? Exerc Sport Sci Rev 30: 184-190, 2002.
94
133. Kalapotharakos VI, Michalopoulos M, Tokmakidis SP, Godolias G and
Gourgoulis V. Effects of a heavy and a moderate resistance training on functional
performance in older adults. J Strength Cond Res 19: 652-657, 2005.
134. Kalapotharakos VI, Michalopoulos M, Tokmakidis SP, Godolias G and
Gourgoulis V. Effects of a heavy and a moderate resistance training on functional
performance in older adults. J Strength Cond Res 19: 652-657, 2005.
135. Kalapotharakos VI, Michalopoulos M, Tokmakidis SP, Godolias G and
Gourgoulis V. Effects of a heavy and a moderate resistance training on functional
performance in older adults. J Strength Cond Res 19: 652-657, 2005.
136. Kalapotharakos VI, Michalopoulos M, Tokmakidis SP, Godolias G and
Gourgoulis V. Effects of a heavy and a moderate resistance training on functional
performance in older adults. J Strength Cond Res 19: 652-657, 2005.
137. Kallman DA, Plato CC and Tobin JD. The role of muscle loss in the age-related
decline of grip strength: cross-sectional and longitudinal perspectives. J Gerontol
45: M82-M88, 1990.
138. Katsuya T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R, Horiuchi M, Pratt
RE, Dzau VJ and MacMahon S. Association of angiotensinogen gene T235
variant with increased risk of coronary heart disease. Lancet 345: 1600-1603,
1995.
95
139. Kehayias JJ, Fiatarone MA, Zhuang H and Roubenoff R. Total body potassium
and body fat: relevance to aging. Am J Clin Nutr 66: 904-910, 1997.
140. Kostek MC, Delmonico MJ, Reichel JB, Roth SM, Douglass L, Ferrell RE and
Hurley BF. Muscle strength response to strength training is influenced by insulin-
like growth factor 1 genotype in older adults. J Appl Physiol 98: 2147-2154, 2005.
141. Kostek MC, Delmonico MJ, Reichel JB, Roth SM, Douglass L, Ferrell RE and
Hurley BF. Muscle strength response to strength training is influenced by insulin-
like growth factor 1 genotype in older adults. J Appl Physiol 98: 2147-2154, 2005.
142. Kostek MC, Delmonico MJ, Reichel JB, Roth SM, Douglass L, Ferrell RE and
Hurley BF. Muscle strength response to strength training is influenced by insulin-
like growth factor 1 genotype in older adults. J Appl Physiol 98: 2147-2154, 2005.
143. Kostek MC, Delmonico MJ, Reichel JB, Roth SM, Douglass L, Ferrell RE and
Hurley BF. Muscle strength response to strength training is influenced by insulin-
like growth factor 1 genotype in older adults. J Appl Physiol 98: 2147-2154, 2005.
144. Kotler DP, Tierney AR, Wang J and Pierson RN, Jr. Magnitude of body-cell-mass
depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 50: 444-
447, 1989.
96
145. Lamoureux EL, Sparrow WA, Murphy A and Newton RU. Differences in the
neuromuscular capacity and lean muscle tissue in old and older community-
dwelling adults. J Gerontol 56A: M381-M385, 2001.
146. Lamoureux EL, Sparrow WA, Murphy A and Newton RU. The relationship
between lower body strength and obstructed gait in community-dwelling older
adults. J Am Geriatr Soc 50: 468-473, 2002.
147. Lamoureux EL, Sparrow WA, Murphy A and Newton RU. The relationship
between lower body strength and obstructed gait in community-dwelling older
adults. J Am Geriatr Soc 50: 468-473, 2002.
148. Lamoureux EL, Sparrow WA, Murphy A and Newton RU. The relationship
between lower body strength and obstructed gait in community-dwelling older
adults. J Am Geriatr Soc 50: 468-473, 2002.
149. Lamoureux EL, Sparrow WA, Murphy A and Newton RU. The relationship
between lower body strength and obstructed gait in community-dwelling older
adults. J Am Geriatr Soc 50: 468-473, 2002.
150. Lamoureux EL, Sparrow WA, Murphy A and Newton RU. The relationship
between lower body strength and obstructed gait in community-dwelling older
adults. J Am Geriatr Soc 50: 468-473, 2002.
97
151. Larsson L, Grimby G and Karlsson J. Muscle strength and speed of movement in
relation to age and muscle morphology. J Appl Physiol 46: 451-456, 1979.
152. Larsson L, Grimby G and Karlsson J. Muscle strength and speed of movement in
relation to age and muscle morphology. J Appl Physiol 46: 451-456, 1979.
153. Larsson L, Grimby G and Karlsson J. Muscle strength and speed of movement in
relation to age and muscle morphology. J Appl Physiol 46: 451-456, 1979.
154. Lemmer JT, Hurlbut DE, Martel GF, Tracy BL, Ivey FM, Metter EJ, Fozard JL,
Fleg JL and Hurley BF. Age and gender responses to strength training and
detraining. Med Sci Sports Exerc 32: 1505-1512, 2000.
155. Lemmer JT, Hurlbut DE, Martel GF, Tracy BL, Ivey FM, Metter EJ, Fozard JL,
Fleg JL and Hurley BF. Age and gender responses to strength training and
detraining. Med Sci Sports Exerc 32: 1505-1512, 2000.
156. Lindle RS, Metter EJ, Lynch NA, Fleg JL, Fozard JL, Tobin J, Roy TA and
Hurley BF. Age and gender comparisons of muscle strength in 654 women and
men aged 20-93 yr. J Appl Physiol 83: 1581-1587, 1997.
157. Lindle RS, Metter EJ, Lynch NA, Fleg JL, Fozard JL, Tobin J, Roy TA and
Hurley BF. Age and gender comparisons of muscle strength in 654 women and
men aged 20-93 yr. J Appl Physiol 83: 1581-1587, 1997.
98
158. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F,
Buring J and Hennekens CH. A prospective evaluation of an angiotensin-
converting-enzyme gene polymorphism and the risk of ischemic heart disease. N
Engl J Med 332: 706-711, 1995.
159. Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F,
Buring J and Hennekens CH. A prospective evaluation of an angiotensin-
converting-enzyme gene polymorphism and the risk of ischemic heart disease. N
Engl J Med 332: 706-711, 1995.
160. Loos R, Thomis M, Maes HH, Beunen G, Claessens AL, Derom C, Legius E,
Derom R and Vlietinck R. Gender-specific regional changes in genetic structure
of muscularity in early adolescence. J Appl Physiol 82: 1802-1810, 1997.
161. Loos R, Thomis M, Maes HH, Beunen G, Claessens AL, Derom C, Legius E,
Derom R and Vlietinck R. Gender-specific regional changes in genetic structure
of muscularity in early adolescence. J Appl Physiol 82: 1802-1810, 1997.
162. Lord SR, Ward JA, Williams P and Strudwick M. The effect of a 12-month
exercise trial on balance, strength, and falls in older women: a randomized
controlled trial. J Am Geriatr Soc 43: 1198-1206, 1995.
99
163. Lord SR, Ward JA, Williams P and Strudwick M. The effect of a 12-month
exercise trial on balance, strength, and falls in older women: a randomized
controlled trial. J Am Geriatr Soc 43: 1198-1206, 1995.
164. Luthi JM, Howald H, Claassen H, Rosler K, Vock P and Hoppeler H. Structural
changes in skeletal muscle tissue with heavy-resistance exercise. Int J Sports Med
7: 123-127, 1986.
165. Luthi JM, Howald H, Claassen H, Rosler K, Vock P and Hoppeler H. Structural
changes in skeletal muscle tissue with heavy-resistance exercise. Int J Sports Med
7: 123-127, 1986.
166. Lynch NA, Metter EJ, Lindle RS, Fozard JL, Tobin JD, Roy TA, Fleg JL and
Hurley BF. Muscle quality. I. Age-associated differences between arm and leg
muscle groups. J Appl Physiol 86: 188-194, 1999.
167. Lynch NA, Metter EJ, Lindle RS, Fozard JL, Tobin JD, Roy TA, Fleg JL and
Hurley BF. Muscle quality. I. Age-associated differences between arm and leg
muscle groups. J Appl Physiol 86: 188-194, 1999.
168. Lynch NA, Metter EJ, Lindle RS, Fozard JL, Tobin JD, Roy TA, Fleg JL and
Hurley BF. Muscle quality. I. Age-associated differences between arm and leg
muscle groups. J Appl Physiol 86: 188-194, 1999.
100
169. Maes HH, Beunen GP, Vlietinck RF, Neale MC, Thomis M, Vanden EB, Lysens
R, Simons J, Derom C and Derom R. Inheritance of physical fitness in 10-yr-old
twins and their parents. Med Sci Sports Exerc 28: 1479-1491, 1996.
170. Maes HH, Beunen GP, Vlietinck RF, Neale MC, Thomis M, Vanden EB, Lysens
R, Simons J, Derom C and Derom R. Inheritance of physical fitness in 10-yr-old
twins and their parents. Med Sci Sports Exerc 28: 1479-1491, 1996.
171. Mathew J, Basheeruddin K and Prabhakar S. Differences in frequency of the
deletion polymorphism of the angiotensin-converting enzyme gene in different
ethnic groups. Angiology 52: 375-379, 2001.
172. Mathew J, Basheeruddin K and Prabhakar S. Differences in frequency of the
deletion polymorphism of the angiotensin-converting enzyme gene in different
ethnic groups. Angiology 52: 375-379, 2001.
173. Mathew J, Basheeruddin K and Prabhakar S. Differences in frequency of the
deletion polymorphism of the angiotensin-converting enzyme gene in different
ethnic groups. Angiology 52: 375-379, 2001.
174. Mattu RK, Needham EW, Galton DJ, Frangos E, Clark AJ and Caulfield M. A
DNA variant at the angiotensin-converting enzyme gene locus associates with
coronary artery disease in the Caerphilly Heart Study. Circulation 91: 270-274,
1995.
101
175. Mattu RK, Needham EW, Galton DJ, Frangos E, Clark AJ and Caulfield M. A
DNA variant at the angiotensin-converting enzyme gene locus associates with
coronary artery disease in the Caerphilly Heart Study. Circulation 91: 270-274,
1995.
176. Maughan RJ, Watson JS and Weir J. Strength and cross-sectional area of human
skeletal muscle. J Physiol 338: 37-49, 1983.
177. Maughan RJ, Watson JS and Weir J. Strength and cross-sectional area of human
skeletal muscle. J Physiol 338: 37-49, 1983.
178. Mazzeo RS and Tanaka H. Exercise prescription for the elderly: current
recommendations. Sports Med 31: 809-818, 2001.
179. McBride TA. AT1 receptors are necessary for eccentric training-induced
hypertrophy and strength gains in rat skeletal muscle. Exp Physiol 91: 413-421,
2006.
180. McBride TA. AT1 receptors are necessary for eccentric training-induced
hypertrophy and strength gains in rat skeletal muscle. Exp Physiol 91: 413-421,
2006.
102
181. McBride TA. AT1 receptors are necessary for eccentric training-induced
hypertrophy and strength gains in rat skeletal muscle. Exp Physiol 91: 413-421,
2006.
182. McBride TA. AT1 receptors are necessary for eccentric training-induced
hypertrophy and strength gains in rat skeletal muscle. Exp Physiol 91: 413-421,
2006.
183. McBride TA. AT1 receptors are necessary for eccentric training-induced
hypertrophy and strength gains in rat skeletal muscle. Exp Physiol 91: 413-421,
2006.
184. McBride TA. AT1 receptors are necessary for eccentric training-induced
hypertrophy and strength gains in rat skeletal muscle. Exp Physiol 91: 413-421,
2006.
185. McEwan PE, Gray GA, Sherry L, Webb DJ and Kenyon CJ. Differential effects
of angiotensin II on cardiac cell proliferation and intramyocardial perivascular
fibrosis in vivo. Circulation 98: 2765-2773, 1998.
186. McEwan PE, Gray GA, Sherry L, Webb DJ and Kenyon CJ. Differential effects
of angiotensin II on cardiac cell proliferation and intramyocardial perivascular
fibrosis in vivo. Circulation 98: 2765-2773, 1998.
103
187. Metter EJ, Conwit R, Tobin J and Fozard JL. Age-associated loss of power and
strength in the upper extremities in women and men. J Gerontol A Biol Sci Med
Sci 52: B267-B276, 1997.
188. Miettinen HE, Korpela K, Hamalainen L and Kontula K. Polymorphisms of the
apolipoprotein and angiotensin converting enzyme genes in young North Karelian
patients with coronary heart disease. Hum Genet 94: 189-192, 1994.
189. Montgomery HE, Clarkson P, Dollery CM, Prasad K, Losi MA, Hemingway H,
Statters D, Jubb M, Girvain M, Varnava A, World M, Deanfield J, Talmud P,
McEwan JR, McKenna WJ and Humphries S. Association of angiotensin-
converting enzyme gene I/D polymorphism with change in left ventricular mass
in response to physical training. Circulation 96: 741-747, 1997.
190. Montgomery HE, Clarkson P, Dollery CM, Prasad K, Losi MA, Hemingway H,
Statters D, Jubb M, Girvain M, Varnava A, World M, Deanfield J, Talmud P,
McEwan JR, McKenna WJ and Humphries S. Association of angiotensin-
converting enzyme gene I/D polymorphism with change in left ventricular mass
in response to physical training. Circulation 96: 741-747, 1997.
191. Montgomery HE, Clarkson P, Dollery CM, Prasad K, Losi MA, Hemingway H,
Statters D, Jubb M, Girvain M, Varnava A, World M, Deanfield J, Talmud P,
McEwan JR, McKenna WJ and Humphries S. Association of angiotensin-
104
converting enzyme gene I/D polymorphism with change in left ventricular mass
in response to physical training. Circulation 96: 741-747, 1997.
192. Montgomery HE, Clarkson P, Dollery CM, Prasad K, Losi MA, Hemingway H,
Statters D, Jubb M, Girvain M, Varnava A, World M, Deanfield J, Talmud P,
McEwan JR, McKenna WJ and Humphries S. Association of angiotensin-
converting enzyme gene I/D polymorphism with change in left ventricular mass
in response to physical training. Circulation 96: 741-747, 1997.
193. Montgomery HE, Clarkson P, Dollery CM, Prasad K, Losi MA, Hemingway H,
Statters D, Jubb M, Girvain M, Varnava A, World M, Deanfield J, Talmud P,
McEwan JR, McKenna WJ and Humphries S. Association of angiotensin-
converting enzyme gene I/D polymorphism with change in left ventricular mass
in response to physical training. Circulation 96: 741-747, 1997.
194. Murphey LJ, Gainer JV, Vaughan DE and Brown NJ. Angiotensin-converting
enzyme insertion/deletion polymorphism modulates the human in vivo
metabolism of bradykinin. Circulation 102: 829-832, 2000.
195. Murphey LJ, Gainer JV, Vaughan DE and Brown NJ. Angiotensin-converting
enzyme insertion/deletion polymorphism modulates the human in vivo
metabolism of bradykinin. Circulation 102: 829-832, 2000.
105
196. Myerson S, Hemingway H, Budget R, Martin J, Humphries S and Montgomery
H. Human angiotensin I-converting enzyme gene and endurance performance. J
Appl Physiol 87: 1313-1316, 1999.
197. Myerson S, Hemingway H, Budget R, Martin J, Humphries S and Montgomery
H. Human angiotensin I-converting enzyme gene and endurance performance. J
Appl Physiol 87: 1313-1316, 1999.
198. Myerson S, Montgomery HE, Whittingham M, Jubb M, World MJ, Humphries
SE and Pennell DJ. Left ventricular hypertrophy with exercise and ACE gene
insertion/deletion polymorphism: a randomized controlled trial with losartan.
Circulation 103: 226-230, 2001.
199. Myerson S, Montgomery HE, Whittingham M, Jubb M, World MJ, Humphries
SE and Pennell DJ. Left ventricular hypertrophy with exercise and ACE gene
insertion/deletion polymorphism: a randomized controlled trial with losartan.
Circulation 103: 226-230, 2001.
200. Myerson S, Montgomery HE, Whittingham M, Jubb M, World MJ, Humphries
SE and Pennell DJ. Left ventricular hypertrophy with exercise and ACE gene
insertion/deletion polymorphism: a randomized controlled trial with losartan.
Circulation 103: 226-230, 2001.
106
201. Nazarov IB, Woods DR, Montgomery HE, Shneider OV, Kazakov VI, Tomilin
NV and Rogozkin VA. The angiotensin converting enzyme I/D polymorphism in
Russian athletes. Eur J Hum Genet 9: 797-801, 2001.
202. Nazarov IB, Woods DR, Montgomery HE, Shneider OV, Kazakov VI, Tomilin
NV and Rogozkin VA. The angiotensin converting enzyme I/D polymorphism in
Russian athletes. Eur J Hum Genet 9: 797-801, 2001.
203. Nevitt MC, Cummings SR, Kidd S and Black D. Risk factors for recurrent
nonsyncopal falls. A prospective study. JAMA 261: 2663-2668, 1989.
204. Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J,
Carter C, Di BM, Guralnik JM and Pahor M. Relation between use of
angiotensin-converting enzyme inhibitors and muscle strength and physical
function in older women: an observational study. Lancet 359: 926-930, 2002.
205. Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J,
Carter C, Di BM, Guralnik JM and Pahor M. Relation between use of
angiotensin-converting enzyme inhibitors and muscle strength and physical
function in older women: an observational study. Lancet 359: 926-930, 2002.
206. Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J,
Carter C, Di BM, Guralnik JM and Pahor M. Relation between use of
107
angiotensin-converting enzyme inhibitors and muscle strength and physical
function in older women: an observational study. Lancet 359: 926-930, 2002.
207. Paquet JL, Baudouin-Legros M, Brunelle G and Meyer P. Angiotensin II-induced
proliferation of aortic myocytes in spontaneously hypertensive rats. J Hypertens
8: 565-572, 1990.
208. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
209. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
210. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
108
211. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
212. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
213. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
214. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
109
215. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
216. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
217. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
218. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
110
219. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
220. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
221. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
222. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
111
223. Pescatello LS, Kostek MA, Gordish-Dressman H, Thompson PD, Seip RL, Price
TB, Angelopoulos TJ, Clarkson PM, Gordon PM, Moyna NM, Visich PS, Zoeller
RF, Devaney JM and Hoffman EP. ACE ID genotype and the muscle strength and
size response to unilateral resistance training. Med Sci Sports Exerc 38: 1074-
1081, 2006.
224. Pratt RE. Angiotensin II and the control of cardiovascular structure. J Am Soc
Nephrol 10 Suppl 11: S120-S128, 1999.
225. Quinn LS, Ong LD and Roeder RA. Paracrine control of myoblast proliferation
and differentiation by fibroblasts. Dev Biol 140: 8-19, 1990.
226. Rankinen T, Bray MS, Hagberg JM, Perusse L, Roth SM, Wolfarth B and
Bouchard C. The human gene map for performance and health-related fitness
phenotypes: the 2005 update. Med Sci Sports Exerc 38: 1863-1888, 2006.
227. Rankinen T, Bray MS, Hagberg JM, Perusse L, Roth SM, Wolfarth B and
Bouchard C. The human gene map for performance and health-related fitness
phenotypes: the 2005 update. Med Sci Sports Exerc 38: 1863-1888, 2006.
228. Rankinen T, Perusse L, Gagnon J, Chagnon YC, Leon AS, Skinner JS, Wilmore
JH, Rao DC and Bouchard C. Angiotensin-converting enzyme ID polymorphism
and fitness phenotype in the HERITAGE Family Study. J Appl Physiol 88: 1029-
1035, 2000.
112
229. Rankinen T, Perusse L, Gagnon J, Chagnon YC, Leon AS, Skinner JS, Wilmore
JH, Rao DC and Bouchard C. Angiotensin-converting enzyme ID polymorphism
and fitness phenotype in the HERITAGE Family Study. J Appl Physiol 88: 1029-
1035, 2000.
230. Rankinen T, Wolfarth B, Simoneau JA, Maier-Lenz D, Rauramaa R, Rivera MA,
Boulay MR, Chagnon YC, Perusse L, Keul J and Bouchard C. No association
between the angiotensin-converting enzyme ID polymorphism and elite
endurance athlete status. J Appl Physiol 88: 1571-1575, 2000.
231. Rankinen T, Wolfarth B, Simoneau JA, Maier-Lenz D, Rauramaa R, Rivera MA,
Boulay MR, Chagnon YC, Perusse L, Keul J and Bouchard C. No association
between the angiotensin-converting enzyme ID polymorphism and elite
endurance athlete status. J Appl Physiol 88: 1571-1575, 2000.
232. Rantanen T, Avlund K, Suominen H, Schroll M, Frandin K and Pertti E. Muscle
strength as a predictor of onset of ADL dependence in people aged 75 years.
Aging Clin Exp Res 14: 10-15, 2002.
233. Rantanen T, Era P and Kauppinen M. Maximal isometric muscle strength and
socio-economic status, health, and physical activity in 75-year-old persons. J
Aging Phys Act 281: 558-560, 1994.
113
234. Rantanen T, Guralnik JM, Sakari-Rantala R, Leveille S, Simonsick EM, Ling S
and Fried LP. Disability, physical activity, and muscle strength in older women:
the Women's Health and Aging Study. Arch Phys Med Rehabil 80: 130-135,
1999.
235. Rantanen T, Guralnik JM, Sakari-Rantala R, Leveille S, Simonsick EM, Ling S
and Fried LP. Disability, physical activity, and muscle strength in older women:
the Women's Health and Aging Study. Arch Phys Med Rehabil 80: 130-135,
1999.
236. Rantanen T, Volpato S, Ferrucci L, Heikkinen E, Fried LP and Guralnik JM.
Handgrip strength and cause-specific and total mortality in older disabled women:
exploring the mechanism. J Am Geriatr Soc 51: 636-641, 2003.
237. Rantanen T, Volpato S, Ferrucci L, Heikkinen E, Fried LP and Guralnik JM.
Handgrip strength and cause-specific and total mortality in older disabled women:
exploring the mechanism. J Am Geriatr Soc 51: 636-641, 2003.
238. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman LS,
Taft CS and Perryman MB. Angiotensin-converting enzyme DD genotype in
patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 342: 1073-
1075, 1993.
114
239. Reed RL, Pearlmutter L, Yochum K, Meredith KE and Mooradian AD. The
relationship between muscle mass and muscle strength in the elderly. J Am
Geriatr Soc 39: 555-561, 1991.
240. Reed RL, Pearlmutter L, Yochum K, Meredith KE and Mooradian AD. The
relationship between muscle mass and muscle strength in the elderly. J Am
Geriatr Soc 39: 555-561, 1991.
241. Reed T, Fabsitz RR, Selby JV and Carmelli D. Genetic influences and grip
strength norms in the NHLBI twin study males aged 59-69. Ann Hum Biol 18:
425-432, 1991.
242. Reed T, Fabsitz RR, Selby JV and Carmelli D. Genetic influences and grip
strength norms in the NHLBI twin study males aged 59-69. Ann Hum Biol 18:
425-432, 1991.
243. Reed T, Fabsitz RR, Selby JV and Carmelli D. Genetic influences and grip
strength norms in the NHLBI twin study males aged 59-69. Ann Hum Biol 18:
425-432, 1991.
244. Reeves ND, Narici MV and Maganaris CN. Effect of resistance training on
skeletal muscle-specific force in elderly humans. J Appl Physiol 96: 885-892,
2004.
115
245. Reneland R and Lithell H. Angiotensin-converting enzyme in human skeletal
muscle. A simple in vitro assay of activity in needle biopsy specimens. Scand J
Clin Lab Invest 54: 105-111, 1994.
246. Reneland R and Lithell H. Angiotensin-converting enzyme in human skeletal
muscle. A simple in vitro assay of activity in needle biopsy specimens. Scand J
Clin Lab Invest 54: 105-111, 1994.
247. Rigat B, Hubert C, Corvol P and Soubrier F. PCR detection of the
insertion/deletion polymorphism of the human angiotensin converting enzyme
gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 20: 1433, 1992.
248. Rigat B, Hubert C, Corvol P and Soubrier F. PCR detection of the
insertion/deletion polymorphism of the human angiotensin converting enzyme
gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucleic Acids Res 20: 1433, 1992.
249. Rigat B, Hubert C, henc-Gelas F, Cambien F, Corvol P and Soubrier F. An
insertion/deletion polymorphism in the angiotensin I-converting enzyme gene
accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-
1346, 1990.
250. Rigat B, Hubert C, henc-Gelas F, Cambien F, Corvol P and Soubrier F. An
insertion/deletion polymorphism in the angiotensin I-converting enzyme gene
116
accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-
1346, 1990.
251. Rigat B, Hubert C, henc-Gelas F, Cambien F, Corvol P and Soubrier F. An
insertion/deletion polymorphism in the angiotensin I-converting enzyme gene
accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-
1346, 1990.
252. Rigat B, Hubert C, henc-Gelas F, Cambien F, Corvol P and Soubrier F. An
insertion/deletion polymorphism in the angiotensin I-converting enzyme gene
accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-
1346, 1990.
253. Roth SM, Ivey FM, Martel GF, Lemmer JT, Hurlbut DE, Siegel EL, Metter EJ,
Fleg JL, Fozard JL, Kostek MC, Wernick DM and Hurley BF. Muscle size
responses to strength training in young and older men and women. J Am Geriatr
Soc 49: 1428-1433, 2001.
254. Roth SM, Ivey FM, Martel GF, Lemmer JT, Hurlbut DE, Siegel EL, Metter EJ,
Fleg JL, Fozard JL, Kostek MC, Wernick DM and Hurley BF. Muscle size
responses to strength training in young and older men and women. J Am Geriatr
Soc 49: 1428-1433, 2001.
117
255. Roth SM, Ivey FM, Martel GF, Lemmer JT, Hurlbut DE, Siegel EL, Metter EJ,
Fleg JL, Fozard JL, Kostek MC, Wernick DM and Hurley BF. Muscle size
responses to strength training in young and older men and women. J Am Geriatr
Soc 49: 1428-1433, 2001.
256. Sadoshima J, Xu Y, Slayter HS and Izumo S. Autocrine release of angiotensin II
mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75: 977-
984, 1993.
257. Sadoshima J, Xu Y, Slayter HS and Izumo S. Autocrine release of angiotensin II
mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75: 977-
984, 1993.
258. Sadoshima J, Xu Y, Slayter HS and Izumo S. Autocrine release of angiotensin II
mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75: 977-
984, 1993.
259. Sadoshima J, Xu Y, Slayter HS and Izumo S. Autocrine release of angiotensin II
mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75: 977-
984, 1993.
260. Sadoshima J, Xu Y, Slayter HS and Izumo S. Autocrine release of angiotensin II
mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75: 977-
984, 1993.
118
261. Samani NJ, O'Toole L, Martin D, Rai H, Fletcher S, Lodwick D, Thompson JR,
Morice AH, Channer K and Woods KL. Insertion/deletion polymorphism in the
angiotensin-converting enzyme gene and risk of and prognosis after myocardial
infarction. J Am Coll Cardiol 28: 338-344, 1996.
262. Sanchez-Andres A and Mesa MS. Heritabilities of morphological and body
composition characteristics in a Spanish population. Anthropol Anz 52: 341-349,
1994.
263. Sanchez-Andres A and Mesa MS. Heritabilities of morphological and body
composition characteristics in a Spanish population. Anthropol Anz 52: 341-349,
1994.
264. Sanchez-Andres A and Mesa MS. Heritabilities of morphological and body
composition characteristics in a Spanish population. Anthropol Anz 52: 341-349,
1994.
265. Sanders PM, Russell ST and Tisdale MJ. Angiotensin II directly induces muscle
protein catabolism through the ubiquitin-proteasome proteolytic pathway and may
play a role in cancer cachexia. Br J Cancer 93: 425-434, 2005.
266. Sanders PM, Russell ST and Tisdale MJ. Angiotensin II directly induces muscle
protein catabolism through the ubiquitin-proteasome proteolytic pathway and may
play a role in cancer cachexia. Br J Cancer 93: 425-434, 2005.
119
267. Sanders PM, Russell ST and Tisdale MJ. Angiotensin II directly induces muscle
protein catabolism through the ubiquitin-proteasome proteolytic pathway and may
play a role in cancer cachexia. Br J Cancer 93: 425-434, 2005.
268. Sanders PM, Russell ST and Tisdale MJ. Angiotensin II directly induces muscle
protein catabolism through the ubiquitin-proteasome proteolytic pathway and may
play a role in cancer cachexia. Br J Cancer 93: 425-434, 2005.
269. Sasaki H, Kasagi F, Yamada M and Fujita S. Grip strength predicts cause-specific
mortality in middle-aged and elderly persons. Am J Med 120: 337-342, 2007.
270. Sasaki H, Kasagi F, Yamada M and Fujita S. Grip strength predicts cause-specific
mortality in middle-aged and elderly persons. Am J Med 120: 337-342, 2007.
271. Sayed-Tabatabaei FA, Oostra BA, Isaacs A, van Duijn CM and Witteman JC.
ACE polymorphisms. Circ Res 98: 1123-1133, 2006.
272. Schenkman M, Hughes MA, Samsa G and Studenski S. The relative importance
of strength and balance in chair rise by functionally impaired older individuals. J
Am Geriatr Soc 44: 1441-1446, 1996.
273. Schenkman M, Hughes MA, Samsa G and Studenski S. The relative importance
of strength and balance in chair rise by functionally impaired older individuals. J
Am Geriatr Soc 44: 1441-1446, 1996.
120
274. Silva GJ, Moreira ED, Pereira AC, Mill JG, Krieger EM and Krieger JE. ACE
gene dosage modulates pressure-induced cardiac hypertrophy in mice and men.
Physiol Genomics 27: 237-244, 2006.
275. Silva GJ, Moreira ED, Pereira AC, Mill JG, Krieger EM and Krieger JE. ACE
gene dosage modulates pressure-induced cardiac hypertrophy in mice and men.
Physiol Genomics 27: 237-244, 2006.
276. Silva GJ, Moreira ED, Pereira AC, Mill JG, Krieger EM and Krieger JE. ACE
gene dosage modulates pressure-induced cardiac hypertrophy in mice and men.
Physiol Genomics 27: 237-244, 2006.
277. Silva GJ, Moreira ED, Pereira AC, Mill JG, Krieger EM and Krieger JE. ACE
gene dosage modulates pressure-induced cardiac hypertrophy in mice and men.
Physiol Genomics 27: 237-244, 2006.
278. Song YH, Li Y, Du J, Mitch WE, Rosenthal N and Delafontaine P. Muscle-
specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle
wasting. J Clin Invest 115: 451-458, 2005.
279. Song YH, Li Y, Du J, Mitch WE, Rosenthal N and Delafontaine P. Muscle-
specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle
wasting. J Clin Invest 115: 451-458, 2005.
121
280. Song YH, Li Y, Du J, Mitch WE, Rosenthal N and Delafontaine P. Muscle-
specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle
wasting. J Clin Invest 115: 451-458, 2005.
281. Staron RS, Malicky ES, Leonardi MJ, Falkel JE, Hagerman FC and Dudley GA.
Muscle hypertrophy and fast fiber type conversions in heavy resistance-trained
women. Eur J Appl Physiol Occup Physiol 60: 71-79, 1990.
282. Tellado JM, Garcia-Sabrido JL, Hanley JA, Shizgal HM and Christou NV.
Predicting mortality based on body composition analysis. Ann Surg 209: 81-87,
1989.
283. Tesch PA. Skeletal muscle adaptations consequent to long-term heavy resistance
exercise. Med Sci Sports Exerc 20: S132-S134, 1988.
284. Tesch PA. Skeletal muscle adaptations consequent to long-term heavy resistance
exercise. Med Sci Sports Exerc 20: S132-S134, 1988.
285. Tesch PA. Skeletal muscle adaptations consequent to long-term heavy resistance
exercise. Med Sci Sports Exerc 20: S132-S134, 1988.
286. Tesch PA, Ekberg A, Lindquist DM and Trieschmann JT. Muscle hypertrophy
following 5-week resistance training using a non-gravity-dependent exercise
system. Acta Physiol Scand 180: 89-98, 2004.
122
287. Tesch PA, Trieschmann JT and Ekberg A. Hypertrophy of chronically unloaded
muscle subjected to resistance exercise. J Appl Physiol 96: 1451-1458, 2004.
288. Thibault MC, Simoneau JA, Cote C, Boulay MR, Lagasse P, Marcotte M and
Bouchard C. Inheritance of human muscle enzyme adaptation to isokinetic
strength training. Hum Hered 36: 341-347, 1986.
289. Thomis MA, Beunen GP, Maes HH, Blimkie CJ, Van LM, Claessens AL,
Marchal G, Willems E and Vlietinck RF. Strength training: importance of genetic
factors. Med Sci Sports Exerc 30: 724-731, 1998.
290. Thomis MA, Beunen GP, Maes HH, Blimkie CJ, Van LM, Claessens AL,
Marchal G, Willems E and Vlietinck RF. Strength training: importance of genetic
factors. Med Sci Sports Exerc 30: 724-731, 1998.
291. Thomis MA, Beunen GP, Maes HH, Blimkie CJ, Van LM, Claessens AL,
Marchal G, Willems E and Vlietinck RF. Strength training: importance of genetic
factors. Med Sci Sports Exerc 30: 724-731, 1998.
292. Thomis MA, Beunen GP, Maes HH, Blimkie CJ, Van LM, Claessens AL,
Marchal G, Willems E and Vlietinck RF. Strength training: importance of genetic
factors. Med Sci Sports Exerc 30: 724-731, 1998.
123
293. Thomis MA, Beunen GP, Maes HH, Blimkie CJ, Van LM, Claessens AL,
Marchal G, Willems E and Vlietinck RF. Strength training: importance of genetic
factors. Med Sci Sports Exerc 30: 724-731, 1998.
294. Thomis MA, Beunen GP, Maes HH, Blimkie CJ, Van LM, Claessens AL,
Marchal G, Willems E and Vlietinck RF. Strength training: importance of genetic
factors. Med Sci Sports Exerc 30: 724-731, 1998.
295. Thomis MA, Beunen GP, Maes HH, Blimkie CJ, Van LM, Claessens AL,
Marchal G, Willems E and Vlietinck RF. Strength training: importance of genetic
factors. Med Sci Sports Exerc 30: 724-731, 1998.
296. Thomis MA, Beunen GP, Maes HH, Blimkie CJ, Van LM, Claessens AL,
Marchal G, Willems E and Vlietinck RF. Strength training: importance of genetic
factors. Med Sci Sports Exerc 30: 724-731, 1998.
297. Thomis MA, Beunen GP, Van LM, Maes HH, Blimkie CJ, Claessens AL,
Marchal G, Willems E and Vlietinck RF. Inheritance of static and dynamic arm
strength and some of its determinants. Acta Physiol Scand 163: 59-71, 1998.
298. Thomis MA, Beunen GP, Van LM, Maes HH, Blimkie CJ, Claessens AL,
Marchal G, Willems E and Vlietinck RF. Inheritance of static and dynamic arm
strength and some of its determinants. Acta Physiol Scand 163: 59-71, 1998.
124
299. Thomis MA, Beunen GP, Van LM, Maes HH, Blimkie CJ, Claessens AL,
Marchal G, Willems E and Vlietinck RF. Inheritance of static and dynamic arm
strength and some of its determinants. Acta Physiol Scand 163: 59-71, 1998.
300. Thomis MA, Beunen GP, Van LM, Maes HH, Blimkie CJ, Claessens AL,
Marchal G, Willems E and Vlietinck RF. Inheritance of static and dynamic arm
strength and some of its determinants. Acta Physiol Scand 163: 59-71, 1998.
301. Thomis MA, Beunen GP, Van LM, Maes HH, Blimkie CJ, Claessens AL,
Marchal G, Willems E and Vlietinck RF. Inheritance of static and dynamic arm
strength and some of its determinants. Acta Physiol Scand 163: 59-71, 1998.
302. Thomis MA, Beunen GP, Van LM, Maes HH, Blimkie CJ, Claessens AL,
Marchal G, Willems E and Vlietinck RF. Inheritance of static and dynamic arm
strength and some of its determinants. Acta Physiol Scand 163: 59-71, 1998.
303. Thomis MA, Huygens W, Heuninckx S, Chagnon M, Maes HH, Claessens AL,
Vlietinck R, Bouchard C and Beunen GP. Exploration of myostatin
polymorphisms and the angiotensin-converting enzyme insertion/deletion
genotype in responses of human muscle to strength training. Eur J Appl Physiol
92: 267-274, 2004.
304. Thomis MA, Huygens W, Heuninckx S, Chagnon M, Maes HH, Claessens AL,
Vlietinck R, Bouchard C and Beunen GP. Exploration of myostatin
125
polymorphisms and the angiotensin-converting enzyme insertion/deletion
genotype in responses of human muscle to strength training. Eur J Appl Physiol
92: 267-274, 2004.
305. Thomis MA, Huygens W, Heuninckx S, Chagnon M, Maes HH, Claessens AL,
Vlietinck R, Bouchard C and Beunen GP. Exploration of myostatin
polymorphisms and the angiotensin-converting enzyme insertion/deletion
genotype in responses of human muscle to strength training. Eur J Appl Physiol
92: 267-274, 2004.
306. Thomis MA, Huygens W, Heuninckx S, Chagnon M, Maes HH, Claessens AL,
Vlietinck R, Bouchard C and Beunen GP. Exploration of myostatin
polymorphisms and the angiotensin-converting enzyme insertion/deletion
genotype in responses of human muscle to strength training. Eur J Appl Physiol
92: 267-274, 2004.
307. Thomis MA, Huygens W, Heuninckx S, Chagnon M, Maes HH, Claessens AL,
Vlietinck R, Bouchard C and Beunen GP. Exploration of myostatin
polymorphisms and the angiotensin-converting enzyme insertion/deletion
genotype in responses of human muscle to strength training. Eur J Appl Physiol
92: 267-274, 2004.
308. Thomis MA, Huygens W, Heuninckx S, Chagnon M, Maes HH, Claessens AL,
Vlietinck R, Bouchard C and Beunen GP. Exploration of myostatin
126
polymorphisms and the angiotensin-converting enzyme insertion/deletion
genotype in responses of human muscle to strength training. Eur J Appl Physiol
92: 267-274, 2004.
309. Thomis MA, Huygens W, Heuninckx S, Chagnon M, Maes HH, Claessens AL,
Vlietinck R, Bouchard C and Beunen GP. Exploration of myostatin
polymorphisms and the angiotensin-converting enzyme insertion/deletion
genotype in responses of human muscle to strength training. Eur J Appl Physiol
92: 267-274, 2004.
310. Thomis MA, Huygens W, Heuninckx S, Chagnon M, Maes HH, Claessens AL,
Vlietinck R, Bouchard C and Beunen GP. Exploration of myostatin
polymorphisms and the angiotensin-converting enzyme insertion/deletion
genotype in responses of human muscle to strength training. Eur J Appl Physiol
92: 267-274, 2004.
311. Thomis MA, Huygens W, Heuninckx S, Chagnon M, Maes HH, Claessens AL,
Vlietinck R, Bouchard C and Beunen GP. Exploration of myostatin
polymorphisms and the angiotensin-converting enzyme insertion/deletion
genotype in responses of human muscle to strength training. Eur J Appl Physiol
92: 267-274, 2004.
312. Thomis MA, Huygens W, Heuninckx S, Chagnon M, Maes HH, Claessens AL,
Vlietinck R, Bouchard C and Beunen GP. Exploration of myostatin
127
polymorphisms and the angiotensin-converting enzyme insertion/deletion
genotype in responses of human muscle to strength training. Eur J Appl Physiol
92: 267-274, 2004.
313. Thorstensson A, Hulten B, von DW and Karlsson J. Effect of strength training on
enzyme activities and fibre characteristics in human skeletal muscle. Acta Physiol
Scand 96: 392-398, 1976.
314. Thorstensson A, Hulten B, von DW and Karlsson J. Effect of strength training on
enzyme activities and fibre characteristics in human skeletal muscle. Acta Physiol
Scand 96: 392-398, 1976.
315. Tiainen K, Sipila S, Alen M, Heikkinen E, Kaprio J, Koskenvuo M, Tolvanen A,
Pajala S and Rantanen T. Heritability of maximal isometric muscle strength in
older female twins. J Appl Physiol 96: 173-180, 2004.
316. Tian XL, Pinto YM, Costerousse O, Franz WM, Lippoldt A, Hoffmann S, Unger
T and Paul M. Over-expression of angiotensin converting enzyme-1 augments
cardiac hypertrophy in transgenic rats. Hum Mol Genet 13: 1441-1450, 2004.
317. Tian XL, Pinto YM, Costerousse O, Franz WM, Lippoldt A, Hoffmann S, Unger
T and Paul M. Over-expression of angiotensin converting enzyme-1 augments
cardiac hypertrophy in transgenic rats. Hum Mol Genet 13: 1441-1450, 2004.
128
318. Tian XL, Pinto YM, Costerousse O, Franz WM, Lippoldt A, Hoffmann S, Unger
T and Paul M. Over-expression of angiotensin converting enzyme-1 augments
cardiac hypertrophy in transgenic rats. Hum Mol Genet 13: 1441-1450, 2004.
319. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F and Soubrier F.
Evidence, from combined segregation and linkage analysis, that a variant of the
angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J
Hum Genet 51: 197-205, 1992.
320. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F and Soubrier F.
Evidence, from combined segregation and linkage analysis, that a variant of the
angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J
Hum Genet 51: 197-205, 1992.
321. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F and Soubrier F.
Evidence, from combined segregation and linkage analysis, that a variant of the
angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J
Hum Genet 51: 197-205, 1992.
322. Tracy BL, Ivey FM, Jeffrey ME, Fleg JL, Siegel EL and Hurley BF. A more
efficient magnetic resonance imaging-based strategy for measuring quadriceps
muscle volume. Med Sci Sports Exerc 35: 425-433, 2003.
129
323. Treuth MS, Ryan AS, Pratley RE, Rubin MA, Miller JP, Nicklas BJ, Sorkin J,
Harman SM, Goldberg AP and Hurley BF. Effects of strength training on total
and regional body composition in older men. J Appl Physiol 77: 614-620, 1994.
324. Treuth MS, Ryan AS, Pratley RE, Rubin MA, Miller JP, Nicklas BJ, Sorkin J,
Harman SM, Goldberg AP and Hurley BF. Effects of strength training on total
and regional body composition in older men. J Appl Physiol 77: 614-620, 1994.
325. Tripathi G, Dharmani P, Khan F, Sharma RK, Pandirikkal V and Agrawal S. High
prevalence of ACE DD genotype among north Indian end stage renal disease
patients. BMC Nephrol 7: 15, 2006.
326. Tsianos G, Sanders J, Dhamrait S, Humphries S, Grant S and Montgomery H. The
ACE gene insertion/deletion polymorphism and elite endurance swimming. Eur J
Appl Physiol 92: 360-362, 2004.
327. Tsianos G, Sanders J, Dhamrait S, Humphries S, Grant S and Montgomery H. The
ACE gene insertion/deletion polymorphism and elite endurance swimming. Eur J
Appl Physiol 92: 360-362, 2004.
328. Tsianos G, Sanders J, Dhamrait S, Humphries S, Grant S and Montgomery H. The
ACE gene insertion/deletion polymorphism and elite endurance swimming. Eur J
Appl Physiol 92: 360-362, 2004.
130
329. Tsianos G, Sanders J, Dhamrait S, Humphries S, Grant S and Montgomery H. The
ACE gene insertion/deletion polymorphism and elite endurance swimming. Eur J
Appl Physiol 92: 360-362, 2004.
330. Vincent KR, Braith RW, Feldman RA, Magyari PM, Cutler RB, Persin SA,
Lennon SL, Gabr AH and Lowenthal DT. Resistance exercise and physical
performance in adults aged 60 to 83. J Am Geriatr Soc 50: 1100-1107, 2002.
331. Vincent KR, Braith RW, Feldman RA, Magyari PM, Cutler RB, Persin SA,
Lennon SL, Gabr AH and Lowenthal DT. Resistance exercise and physical
performance in adults aged 60 to 83. J Am Geriatr Soc 50: 1100-1107, 2002.
332. Vincent KR, Braith RW, Feldman RA, Magyari PM, Cutler RB, Persin SA,
Lennon SL, Gabr AH and Lowenthal DT. Resistance exercise and physical
performance in adults aged 60 to 83. J Am Geriatr Soc 50: 1100-1107, 2002.
333. Vincent KR, Braith RW, Feldman RA, Magyari PM, Cutler RB, Persin SA,
Lennon SL, Gabr AH and Lowenthal DT. Resistance exercise and physical
performance in adults aged 60 to 83. J Am Geriatr Soc 50: 1100-1107, 2002.
334. Vincent KR, Braith RW, Feldman RA, Magyari PM, Cutler RB, Persin SA,
Lennon SL, Gabr AH and Lowenthal DT. Resistance exercise and physical
performance in adults aged 60 to 83. J Am Geriatr Soc 50: 1100-1107, 2002.
131
335. Visser M, Goodpaster BH, Kritchevsky SB, Newman AB, Nevitt M, Rubin SM,
Simonsick EM and Harris TB. Muscle mass, muscle strength, and muscle fat
infiltration as predictors of incident mobility limitations in well-functioning older
persons. J Gerontol A Biol Sci Med Sci 60: 324-333, 2005.
336. Visser M, Kritchevsky SB, Goodpaster BH, Newman AB, Nevitt M, Stamm E
and Harris TB. Leg muscle mass and composition in relation to lower extremity
performance in men and women aged 70 to 79: the health, aging and body
composition study. J Am Geriatr Soc 50: 897-904, 2002.
337. Visser M, Newman AB, Nevitt MC, Kritchevsky SB, Stamm EB, Goodpaster BH
and Harris TB. Reexamining the sarcopenia hypothesis. Muscle mass versus
muscle strength. Health, Aging, and Body Composition Study Research Group.
Ann N Y Acad Sci 904: 456-461, 2000.
338. Westerkamp CM and Gordon SE. Angiotensin-converting enzyme inhibition
attenuates myonuclear addition in overloaded slow-twitch skeletal muscle. Am J
Physiol Regul Integr Comp Physiol 289: R1223-R1231, 2005.
339. Westerkamp CM and Gordon SE. Angiotensin-converting enzyme inhibition
attenuates myonuclear addition in overloaded slow-twitch skeletal muscle. Am J
Physiol Regul Integr Comp Physiol 289: R1223-R1231, 2005.
132
340. Westerkamp CM and Gordon SE. Angiotensin-converting enzyme inhibition
attenuates myonuclear addition in overloaded slow-twitch skeletal muscle. Am J
Physiol Regul Integr Comp Physiol 289: R1223-R1231, 2005.
341. Westerkamp CM and Gordon SE. Angiotensin-converting enzyme inhibition
attenuates myonuclear addition in overloaded slow-twitch skeletal muscle. Am J
Physiol Regul Integr Comp Physiol 289: R1223-R1231, 2005.
342. Westerkamp CM and Gordon SE. Angiotensin-converting enzyme inhibition
attenuates myonuclear addition in overloaded slow-twitch skeletal muscle. Am J
Physiol Regul Integr Comp Physiol 289: R1223-R1231, 2005.
343. Westerkamp CM and Gordon SE. Angiotensin-converting enzyme inhibition
attenuates myonuclear addition in overloaded slow-twitch skeletal muscle. Am J
Physiol Regul Integr Comp Physiol 289: R1223-R1231, 2005.
344. Westerkamp CM and Gordon SE. Angiotensin-converting enzyme inhibition
attenuates myonuclear addition in overloaded slow-twitch skeletal muscle. Am J
Physiol Regul Integr Comp Physiol 289: R1223-R1231, 2005.
345. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
133
346. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
347. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
348. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
349. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
350. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
351. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
134
352. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
353. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
354. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
355. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
356. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
357. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
135
358. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
359. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
360. Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S and Montgomery HE.
Circulating angiotensin converting enzyme activity is correlated with muscle
strength. Med Sci Sports Exerc 37: 944-948, 2005.
361. Williams AG, Rayson MP, Jubb M, World M, Woods DR, Hayward M, Martin J,
Humphries SE and Montgomery HE. The ACE gene and muscle performance.
Nature 403: 614, 2000.
362. Williams AG, Rayson MP, Jubb M, World M, Woods DR, Hayward M, Martin J,
Humphries SE and Montgomery HE. The ACE gene and muscle performance.
Nature 403: 614, 2000.
363. Williams AG, Rayson MP, Jubb M, World M, Woods DR, Hayward M, Martin J,
Humphries SE and Montgomery HE. The ACE gene and muscle performance.
Nature 403: 614, 2000.
136
364. Winick Med. Hunger Disease - Studies by Jewish Physicians in the Warsaw
Ghetto. New York: John Wiley & Sons, 1979.
365. Winkelmann BR, Nauck M, Klein B, Russ AP, Bohm BO, Siekmeier R, Ihnken
K, Verho M, Gross W and Marz W. Deletion polymorphism of the angiotensin I-
converting enzyme gene is associated with increased plasma angiotensin-
converting enzyme activity but not with increased risk for myocardial infarction
and coronary artery disease. Ann Intern Med 125: 19-25, 1996.
366. Winkelmann BR, Nauck M, Klein B, Russ AP, Bohm BO, Siekmeier R, Ihnken
K, Verho M, Gross W and Marz W. Deletion polymorphism of the angiotensin I-
converting enzyme gene is associated with increased plasma angiotensin-
converting enzyme activity but not with increased risk for myocardial infarction
and coronary artery disease. Ann Intern Med 125: 19-25, 1996.
367. Woods D, Hickman M, Jamshidi Y, Brull D, Vassiliou V, Jones A, Humphries S
and Montgomery H. Elite swimmers and the D allele of the ACE I/D
polymorphism. Hum Genet 108: 230-232, 2001.
368. Woods DR, Humphries SE and Montgomery HE. The ACE I/D polymorphism
and human physical performance. Trends Endocrinol Metab 11: 416-420, 2000.
369. Woods DR, Humphries SE and Montgomery HE. The ACE I/D polymorphism
and human physical performance. Trends Endocrinol Metab 11: 416-420, 2000.
137
370. Woods DR and Montgomery HE. Angiotensin-converting enzyme and genetics at
high altitude. High Alt Med Biol 2: 201-210, 2001.
371. Woods DR, World M, Rayson MP, Williams AG, Jubb M, Jamshidi Y, Hayward
M, Mary DA, Humphries SE and Montgomery HE. Endurance enhancement
related to the human angiotensin I-converting enzyme I-D polymorphism is not
due to differences in the cardiorespiratory response to training. Eur J Appl Physiol
86: 240-244, 2002.
372. Woods DR, World M, Rayson MP, Williams AG, Jubb M, Jamshidi Y, Hayward
M, Mary DA, Humphries SE and Montgomery HE. Endurance enhancement
related to the human angiotensin I-converting enzyme I-D polymorphism is not
due to differences in the cardiorespiratory response to training. Eur J Appl Physiol
86: 240-244, 2002.
373. Young A. Exercise physiology in geriatric practice. Acta Med Scand [Suppl] 711:
277-232, 1985.
374. Zhai G, Stankovich J, Ding C, Scott F, Cicuttini F and Jones G. The genetic
contribution to muscle strength, knee pain, cartilage volume, bone size, and
radiographic osteoarthritis: a sibpair study. Arthritis Rheum 50: 805-810, 2004.
138
375. Zhai G, Stankovich J, Ding C, Scott F, Cicuttini F and Jones G. The genetic
contribution to muscle strength, knee pain, cartilage volume, bone size, and
radiographic osteoarthritis: a sibpair study. Arthritis Rheum 50: 805-810, 2004.
376. Zhang B, Tanaka H, Shono N, Miura S, Kiyonaga A, Shindo M and Saku K. The
I allele of the angiotensin-converting enzyme gene is associated with an increased
percentage of slow-twitch type I fibers in human skeletal muscle. Clin Genet 63:
139-144, 2003.
377. Zhang B, Tanaka H, Shono N, Miura S, Kiyonaga A, Shindo M and Saku K. The
I allele of the angiotensin-converting enzyme gene is associated with an increased
percentage of slow-twitch type I fibers in human skeletal muscle. Clin Genet 63:
139-144, 2003.
